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Introduction 
Botulinum neurotoxins (BoNTs) are the most potent toxins known and 
are the causative agent of botulism, a serious and potentially fatal 
paralytic disease. The main effect of BoNTs is predominantly exerted as 
inhibitor of acetylcholine (ACh) release from cholinergic nerve endings 
at the skeletal neuromuscular junction (NMJ). The action of BoNTs at 
the NMJ has been extensively investigated and knowledge gained in this 
field laid the basis for the use of BoNTs in human pathologies 
characterized by excessive muscle contractions. Over the past few years, 
therapeutic applications of BoNTs were extended to a wide variety of 
neurological disorders ranging from treatment of overactive skeletal and 
smooth muscles to management of hypersecretory disorders. Pain 
conditions, and particularly neuropathic and intractable pain, are some of 
the pathological states that have been recently treated with BoNTs with 
beneficial effects. Despite both BoNT/A and BoNT/B are commercially 
available, in clinical practice the therapeutic use of BoNT/A is prevalent. 
Development of immunogenicity is an important problem concerning the 
long-term use of BoNT/A. Studies indicate that neutralizing antibodies 
develop in more than 2% of BoNT/A treated patients. The high number 
of patients not responding to this treatment makes it necessary to test 
other BoNT serotypes in clinical practice and BoNT/B was proposed as a 
possible alternative treatment to BoNT/A. However, only a smaller 
number of studies have focused on clinical use of BoNT/B. Therefore, to 
understand the molecular mechanisms whereby BoNT/B alter pain 
processing, and the possible differences between the two serotypes in 
these mechanisms, has become urgent and indispensable. 
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 Historical overview and classification 
Botulinum neurotoxins (BoNTs) are produced by different species of 
anaerobic Gram-positive bacteria belonging to the genus Clostridium. 
These bacteria, and in particular their spores, are spread in soil, water, 
vegetation and in the intestinal tract of many animals (Rossetto et al., 
2014). In 1895 van Ermengem identified and isolated for the first time 
the bacterium responsible for botulism, Clostridium botulinum. Five 
years later two different bacterial neurotoxins, subsequently nominated 
as type A and B, have been discovered and in the following years other 
serotypes of BoNT produced by different species of clostridia have been 
identified (Bentivoglio et al., 2015). BoNTs have been classified on the 
basis of specific antibody recognition and each serotype is identified by a 
letter (from A to G). Recently, an additional BoNT serotype (H) has been 
discovered, however this result must be confirmed (Montecucco & 
Rasotto, 2015). BoNT/G, isolated by Gimenez and Ciccarelli in 1969 
from a cornfield in Argentina (Ciccarelli et al., 1977), is the only one 
BoNT produced by Clostridium argentinense; the other BoNT serotypes 
are produced by Clostridium botulinum, Clostridium baratii and 
Clostridium butyricum. These bacterial species were divided into 6 
groups according to the fermentation process used and to toxin produced. 
Although most strains of Clostridium botulinum express a single toxin 
serotype, some strains can produce a mixture of BoNT subtypes or 
mosaic toxins (see table 1). 
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Clostridium species 
 Group I 
Proteolytic 
C.botulinum 
Group II 
Non-proteolytic 
C.botulinum 
Group III 
C.botulinum 
Group IV 
C.argentinense 
Group V 
C.butyricum 
Group VI 
C.baratii 
 
Type 
A-B-(H)* 
 
*serotype H 
remains to be 
experimentally 
verified  
 
B-E-F  
 
C/D G E F 
 
Subtype 
A₁→A₁₀ 
B₁→B₃ 
B₅(B)/B₆ 
B₇/A(B) 
Ab/Af/Af₈ 
Bf/F₁→F₅  
 
B₄;E₁→E₃ 
E₆→E₁ 
F₆  
 
C/D 
CD/DC  
 
 E₄/E₅  
 
F₇  
 
 
Table 1. Serotypes and subtypes of BoNT produced by different classes of 
neurotoxigenic Clostridium species. (Adapted from Rossetto et al., 2014).  
BoNTs specifically affect vertebrates but different animal species show a 
great range of sensitivity to the different BoNTs. Serotypes /A, /B, and /E 
are those more frequently associated with human botulism. The most 
common forms of human botulism are food-borne botulism, which 
occurs following the ingestion of food containing the pre-formed toxin, 
and infant botulism, caused by the ingestion of food contaminated with 
clostridia spores that germinate into the gastrointestinal tract where the 
bacterium can proliferate due to the reduced resident microbiota in 
infants (Aureli et al., 1986; Johnson & Montecucco, 2008; Koepke et al., 
2008). Other forms of human botulism are much rarer and include 
inhalational botulism, owing to inhalation of BoNT contained in 
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aerosols, iatrogenic botulism, caused by injections of excessive clinical 
doses of BoNT, and wound botulism, which is almost exclusively 
associated with drug injections (Rossetto et al., 2014). After breaching 
the intestinal epithelial barrier, BoNTs reach the lymphatic and blood 
circulation. Through the circulation the toxins can reach the peripheral 
nervous system (PNS) but cannot enter the central nervous system (CNS) 
because BoNTs are unable to cross the blood-brain barrier (Rossetto et 
al., 2014). The cause of the high toxicity of BoNTs is their absolute 
neurospecificity. In PNS the toxins contact the peripheral cholinergic 
nerve endings and acting inside nerve block acetylcholine release from 
the presynaptic nerve terminal at the neuromuscular junction (Simpson, 
2013). The block of neurotransmitter release, via their activity directed 
specifically on SNARE proteins, induce flaccid paralysis and autonomic 
dysfunctions and, in severe form of botulism the death occurs due to 
respiratory failure (Montecucco & Rasotto, 2015). During the time that 
the toxin is present in blood it is highly stable. Clinical trials have 
provided impressive evidence for stability of the toxin in the human 
body. Fagan et al. (2009) have carried out toxicity assays on serum 
samples from patients diagnosed with type A oral botulism. They were 
able to detect active toxin in the circulation of patients as much as 11 
days after ingestion of tainted food. Sheth et al. (2008) reported the 
presence of active toxin in the serum of a patient even 25 days after onset 
of illness. These clinical trials showed that the toxin enters the circulation 
and remains there intact and biologically active until it is delivered to the 
target cells, or until you delete it from the body. The very long systemic 
half-life of botulinum neurotoxin in the human body can probably be 
attributed to the fact that, even at multi-lethal doses (the 50% lethal dose, 
LD50, in mice and human varies between 0,1 ng and 1 ng of toxin per kg 
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of body weight), the circulating titer of toxin is too low to be easily or 
efficiently revealed by any metabolic system (Simpson, 2013). 
Structure 
Different species of clostridia (botulinum, argentinense, butyricum and 
baratii) produce eight different BoNT serotypes (from A to H). The 
neurotoxins, released via bacterial lysis, are synthesized as a single 
inactive polypeptide chain of 150 kDa. Inactive polypeptide, subjected to 
the action of trypsin or a trypsin-like protease, is cleaved (nicked) and 
transformed into an activated di-chain molecule (DasGupta & Sugiyama 
1972a). Clostridia possess the proteases necessary to activate only some 
toxin serotypes (for example, BoNT/A is released from bacteria as the 
fully active toxin). For some BoNT serotypes, clostridia do not have this 
ability, so, through the bacterial lysis is exclusively released the inactive 
protoxins (BoNT/E is the most well studied of the unnicked toxins, it is 
between one and two orders of magnitude less potent than the nicked 
variant) (Simpson, 2013) or, as type B, only a portion of active 
neurotoxin are produced (Das Gupta & Sugiyama 1972b). Active di-
chain neurotoxin is formed by a 50 kDa light chain (LC) linked by a 
disulphide bond with a 100 kDa heavy chain (HC) (Montecucco et al., 
1994). Structural and biochemical data (Robinson et al., 1988; Schiavo et 
al., 1993) showed that the active neurotoxin di-chain possesses different 
domains that play different roles during cell intoxication. LC domain is 
the catalytic and toxic domain; this is a metalloprotease domain that 
specifically cleaves the necessary proteins to the neurotransmitter 
exocytosis, the SNARE proteins. The HC domain is functionally divided 
into two distinct domains: the translocation HCN domain (the 50 kDa 
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amino-teminal half of the HC chain), required to transport LC across the 
membrane of endocytic vesicles into the neuronal cytosol, and the 
receptor binding HCc domain (the 50 kDa carboxyl-terminal half of the 
HC chain), divided in turn in two different sub-domains,  necessary for 
the binding of the toxin to the nerve cell surface (Pellett et al., 2015; 
Rossetto et al., 2014) (see figure 1).   
 
 
 
Figure 1. Botulinum Neurotoxin serotype A. The 50 kDa light chain (LC, red) is linked 
to the 100 kDa heavy chain (HC, yellow, violet and green) by a disulphide bond. The 
LC chain is the catalytic and toxic domain; The HC chain is functionally divided into 
the translocation domain (HCN, yellow), required for transport of the LC from the 
endosome into the cell cytosol, and the receptor binding domain (HCc), divided in turn 
in two different sub-domains (violet and green), necessary for the binding of the toxin to 
the cell surface (modified from Rossetto et al., 2014). 
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The absolute neurospecificity of BoNTs is the cause of their high 
toxicity. BoNTs only bind to peripheral nerve terminals, particularly 
those of skeletal and autonomic cholinergic nerves (Dolly et al., 1984). 
To bind the presynaptic membrane of peripheral nerves, BoNTs use two 
independent receptors: a polysialoganglioside (PSG) and a protein 
receptor included in the lumen of synaptic vesicles membrane (see figure 
2). PSG molecules are present at a high density on the presynaptic 
membrane and are organized in microdomains that include glycoproteins 
and glycolipids. PSGs act as 'magnets' that attract toxins that pass close 
and concentrate them on the nerve terminal surface. The binding of 
BoNTs to the PSG molecule is rapid: BoNTs bind to the most distal part 
of the PSG sugar head via a PSG-binding site that is located in the HC 
domain of the neurotoxin. Studies of the rat NMJ have shown that 
hundreds of BoNT/A or BoNT/B molecules can bind per square 
micrometer of the presynaptic membrane (Black & Dolly 1986). 
Following attachment to PSG, BoNT/B, /DC and /G bind the secretory 
vesicle protein synaptotagmin (Syt, isoforms I, II,) via a binding site in 
the HCC domain, close to the PSG-binding. The two binding sites of PSG 
and Syt are structurally separated and independent of each other (Dong et 
al., 2003; Rummel et al., 2007). It has been noted that, unlike the mouse 
and rat, human Syt-II is not a high affinity receptor for BoNT/B and /G 
due to a mutation present only in humans and chimpanzees. This 
mutation eliminates one of three main points of interaction between Syt-
II and BoNT/B and it would explain the disparity in potency of BoNT/B 
in humans compared to mice (Strotmeier et al., 2012). BoNT/A and /E 
bind the synaptic vesicle protein SV2 (isoforms A, B, and C) (Dong et 
al., 2006). Although isoform SV2C seems to be the main receptor that is 
involved in BoNT/A binding in vitro via an interaction with the HC 
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domain, both SV2A and SV2B can also mediate BoNT/A entry, and all 
three isoforms are expressed on motor nerve terminals (Dong et al., 2006, 
2008). Glycosylated residues are present in the toxin-binding site of SV2 
and this could be potentially clinically relevant because different pattern 
of glycosylation among individuals would provide a simple explanation 
for the variable sensitivity of different patients to BoNT/A1 injection, 
which is often observed in clinical settings (Rossetto et al., 2014). Syt 
and SV2 are integral proteins of the synaptic vesicle membrane and 
expose their BoNT-binding sites inside the lumen of the vesicle. Unlike 
PSG, these protein receptors are not directly accessible to BoNTs. Syt 
and SV2 become available only after the fusion of the synaptic vesicle 
with the presynaptic membrane, when the vesicular lumen is exposed to 
the extracellular environment. The binding of the toxin to its two 
receptors is needed to the subsequent step of intoxication: the 
endocytosis of BoNTs (Rossetto et al., 2014).  
 
 
 
Figure 2. Binding of botulinum neurotoxins on the surface of peripheral terminals 
nerve (modified from Rossetto et al., 2014). 
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Following binding to the membrane receptors, the neurotoxin is 
internalized in vesicles. To reach its target the toxin has to move his 
catalytic LC domain from the vesicular lumen into the cytosol of nerve 
cells. Acidification of the vesicles, generated by the vesicular ATPase 
proton pump that drives the reentry of neurotransmitter into the synaptic 
vesicle after exocytosis, triggers a conformational change of the HCN 
domain which inserted into the vesicle membrane. The HCN domain 
forms in this way a transmembrane protein channel that allows 
translocation of the LC metalloprotease domain from the vesicular lumen 
inside the cytosol (Montal, 2010). The release of the LC domain into the 
cytosolic side, requires the reduction, and so the cleavage, of the inter-
chain disulphide bond (Fischer & Montal, 2007). The reduction of the 
disulphide bond at any stage before its exposure to the cytosol prevents 
LC translocation, so this domain must emerge on the cytosolic side 
before reduction takes place (Fischer & Montal, 2007). The cleavage of 
inter-chain disulphide bonds is catalyzed in the cytosol cell by different 
enzymatic systems and when this occurs the LC domain translocation is 
irreversible and the toxin is so free to interact with its target, the SNARE 
proteins. 
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SNARE proteins 
SNARE proteins, (Soluble N-ethylmaleimide-sensitive factor Attachment 
protein REceptor), are membrane-associated proteins that participate in 
the fusion of synaptic vesicles with the plasmatic membrane. These 
proteins, on the basis of their locations, were originally classified into 
two categories: vesicle-associated or v-SNARE proteins, incorporated 
into the membranes of transport vesicles, and target-membrane or t-
SNARE proteins, that are proteins associated with nerve terminal 
membranes. A more recent classification, based on the presence of 
arginine (R) or glutamine (Q) residue in a conserved 60-70-amino-acid 
motif, has divided these proteins into: R-SNAREs (generally, but not 
always, on vesicles) and Q-SNAREs (usually at the target membrane) 
(Stow et al., 2006). The synaptic vesicles membrane contains a single R-
SNARE (the synaptobrevin, SYB, also called vesicle-associated 
membrane protein or VAMP) while the plasmatic membrane of the 
neurons contains two different Q-SNAREs (syntaxin and SNAP-25). 
When the vesicles are approaching the plasmatic membrane, SNARE 
proteins interact with each other to form a four-helix parallel bundle 
known as the core complex of SNARE (Sutton et al., 1998). The SNARE 
core complex is formed by ionic interactions between amino acids of 
SNARE motifs of one syntaxin, one VAMP, and two SNAP-25 (Meng & 
Wang, 2015). The core complex is remarkably stable and can be 
separated only by boiling in the presence of sodium dedocyl sulfonate 
(SDS) (Fasshauer et al., 2002). The assembly of synaptobrevin, syntaxin, 
and SNAP-25 into the SNARE complex creates a bridge between the two 
membranes destined to fuse. (see figure 3). 
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Figure 3. Description of molecular assembly of synaptobrevin, syntaxin and SNAP-25 
into the SNARE core complex (modified from the book: 'Molecular Mechanisms of 
Neurotransmitter Release', edited by Zhao Wen Wang). 
 
The cleavage of these proteins by BoNTs causes a failure of core 
complex assembly and a synaptic vesicle exocytosis block (Hayashi et 
al., 1994). Each SNARE protein possesses particular characteristics that 
make it the target of a specific BoNT serotype. 
Synaptobrevin (SYB, also known as VAMP) is a protein of synaptic 
vesicles of 13 kDa. VAMP was originally identified and cloned from 
Torpedo nervous system (Trimble et al., 1988). Later it was found in a 
variety of species including mammals and non-vertebrates species, as 
squid, Aplysia and Drosophila showing a high degree of conservation in 
evolution (Südhof et al., 1989; Elferink et al., 1989; Yamasaki et al., 
1994). The VAMP family consists of many isoforms but only three of 
these have been extensively characterized: VAMP1, VAMP2, and 
VAMP3 (Schiavo et al., 2000). Each of them has distinct functions and 
their expression varies between different species and tissues. For 
example, VAMP1 is expressed in sensory neurons to regulate pain-
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peptide exocytosis and in motor neurons to mediate acetylcholine release 
(Meng et al., 2007; Peng et al., 2014). VAMP2 is mainly expressed in the 
CNS and regulates exocytosis of neurotransmitters from small vesicles 
(Schoch et al., 2001). VAMP3 is widespread outside the nervous system 
and is involved in integrin-mediated cell adhesion (Luftman et al., 2009). 
VAMP proteins contain a short carboxyl-terminal segment located inside 
the vesicle lumen, while most of the molecule is exposed to the cytosol. 
BoNT serotypes /B, /D, /F and /G cleave the cytosolic segment of 
VAMP1, -2 and -3 and release its amino-terminal part into the cytosol 
(see figure 4).  
 
 
 
Figure 4. BoNT/B, /D, /F and /G cleave VAMP1-2 and -3 on the conserved central 
portion of the protein and release its amino-terminal part into the cytosol (modified 
from Binz et al.,2010). 
 
It has been observed that VAMP1 of chicken and rat is insensitive to 
BoNT/B due to a single amino acid replacement at the site of BoNT/B 
cleavage. This amino acid substitution has been proposed to be 
associated with the resistance of rats and chickens to type B botulism, 
which contrasts with the sensitivity of humans and mice (Montecucco et 
al., 1994). Further experiments indicate that a polymorphism at position 
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48 of VAMP1 in rats, renders VAMP1 resistant (I48) or sensitive (M48) 
to BoNT/D. Also the human VAMP1 contains the same I48 
polymorphism, and this may explain why humans are insensitive to 
BoNT/D (Peng et al., 2014). To confirm this, it has been reported that 
synaptic transmission in isolated human nerve-muscle biopsy tissues was 
not blocked by BoNT/D (Coffield et al., 1997) moreover, low doses of 
BoNT/D into the extensor digitorum brevis muscle of human volunteers 
showed no significant paralysis, indicating that humans are indeed 
insensitive to BoNT/D (Sobel, 2005; Eleopra et al., 2013). 
Syntaxin was originally identified as the HPC-1 antigen, in the mouse 
hippocampus and amacrine cells of the retina (Barnstable et al., 1983). 
Afterwards Bennett, in 1992, called this protein syntaxin (STX) (Tagaya 
et al., 1995; Yoshida et al., 1992). Syntaxin is an integral membrane 
protein of 35 kDa, located mainly on the neuronal plasmatic membrane. 
The NH2-terminal portion is exposed to the cytosol and is followed by a 
transmembrane domain and few extracellular residues. Two isoforms of 
different length have been identified in neurons (STX1A and STX1B) 
and a vast polymorphism is present in several other tissues as in 
chromaffin granules (Tagaya et al., 1995), in tissues of the immune 
system, in thymus, in adipose tissue (Rezaei Farimani et al., 2015), in 
spleen and lymph nodes (Bin et al., 2013). It was observed that STX1A 
and STX1B, having a differential distribution in some parts of both 
peripheral and central nervous system (Ruiz-Montasell et al., 1996), play 
distinct roles in supporting neuronal survival by glial cells (Kofuji et al., 
2014).  
Several syntaxin isoforms, including STX1, undergo a complex pattern 
of alternative splicing and this differential expression of the protein could 
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be important for the formation of distinct SNARE complexes with 
different SNAP-25 and VAMP isoforms (Schiavo et al., 2000). The 
syntaxin protein is the target of BoNT/C but various syntaxin isoforms 
show different sensitivity to the neurotoxin: isoforms 1A, 1B, 2, 3 are 
sensitive, while isoforms 4 and 5 are resistant to the toxin cleavage (Blasi 
et al., 1993a; Schiavo et al., 1995). 
BoNT/C cleaves STX1, 2 and 3 at a single site near the cytosolic 
membrane surface causing the release of a large portion of the cytosolic 
domain of the protein (Blasi et al., 1993b) (see figure 5). 
 
 
 
Figure 5. BoNT/C cleaves syntaxin at a single site near the cytosolic membrane surface 
located 12 aminoacids upstream of the C-terminal transmembrane domain between Lys 
253 and Ala 254,. The action of BoNT/ C causes the release of a large portion of the 
cytosolic domain of the protein (modified from  Binz et al., 2010). 
SNAP-25 is a membrane associated protein highly conserved in the 
evolution (Risinger et al., 1993). It was originally characterized and 
located in the presynaptic terminals of mouse hippocampal mossy fibers 
and inner molecular layer of the dentate gyrus (Oyler et al., 1989). 
Subsequently it has been also identified in Drosophila, goldfish, Torpedo 
(Risinger et al., 1993), chicken (Bark, 1993), mouse (Oyler et al., 1989) 
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and in different human tissues (Bark & Wilson 1994; Jacobsson et al., 
1994). SNAP-25 is a 206 residue protein of 25 kDa and, because of the 
absence of a transmembrane segment, its membrane localization is 
mediated by the palmitoylation of cysteine residues located in the middle 
of the polypeptide chain (Patarnello et al., 1993; Lane & Liu, 1997;Oyler 
et al., 1989). There are two isoforms of SNAP-25, SNAP-25a and SNAP-
25b. They are generated by alternative splicing and differ by only nine 
amino acids (Bark, 1993). SNAP-25a appears early in the development 
while the expression of SNAP-25b begins on the onset of synaptogenesis 
(Oyler et al., 1991; Bark et al., 1995). Low levels of SNAP-25a 
expression are also found in the adult brain however, the two isoforms 
localization seems to be different, since SNAP-25a would be localized 
mainly in the cell-bodies of neurons and SNAP-25b would concentrate in 
nerve terminals (Oyler et al., 1989; Bark et al., 1995). Three homologous 
proteins to SNAP-25 have been identified: SNAP-23 (Ravichandran et 
al., 1996; Wang et al., 1997), SNAP-29 (Steegmaier et al., 1998) and 
SNAP-47 (Holt et al., 2006). SNAP-29 and SNAP-47 are involved in 
intracellular vesicle trafficking (Yamamori et al., 2011). In contrast, 
SNAP-23 is ubiquitously expressed in and out of the nervous system and 
participates in exocytosis of various cell types (Suh et al., 2010). In some 
regulated secretory pathways SNAP-23 can replace SNAP-25, thus 
suggesting a partial overlapping in their functions (Sadoul et al., 1997). 
SNAP-25 is substrate of the proteolytic activity of Botulinum 
neurotoxins type /A, /E and /C. Only a small segment of SNAP-25 is 
released by the selective proteolysis of BoNTs (see figure 6). BoNT/A, 
/E and /C cleave SNAP-25 at the carboxyl terminus, with the release of 
nine, twenty-six and eight residues peptides respectively (Blasi et al., 
1993a,b; Binz et al., 1994; Williamson & Neale, 1998). Since the 
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BoNT/A and /C remove only a few residues from the C-terminus of 
SNAP-25 and this truncated form of SNAP-25 can form a stable SNARE 
complex, the molecular mechanism of BoNT/A- and /C-induced 
neuroparalysis remains to be elucidated (Rossetto et al., 2014). 
 
 
 
Figure 6. BoNT/A, /C and /E cleave SNAP-25 at the carboxyl terminus with the release 
of nine, eight and twenty-six residues peptides respectively (modifed from Binz et 
al.,2010). 
The cleavage of SNARE proteins prevents the fusion of the synaptic 
vesicle membrane with the plasmatic membrane and blocks the 
transmitter release. The effect of this block causes a local muscle 
chemodenervation without degeneration of nerve endings (Jankovic, 
2004). Muscle denervation promotes a compensatory sprouting of nerve 
terminals leading to the formation of new synaptic contacts. In 
approximately 3-4 months, when BoNTs are proteolysed and SNARE 
proteins are re-synthetized, there is a full recovery of the original 
neuromuscular junction with regression of the sprouts (Schiavo et al., 
2000). One special feature of BoNTs is the reversibility of their action. 
BoNTs cause flaccid paralysis, which can result in respiratory failure and 
death, however, if respiration is mechanically assisted, botulism patients 
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recover completely from the neuroparalysis, though with different time 
courses depending on the BoNT serotype involved (Johnson & 
Montecucco, 2008). There is a remarkable diversity in the duration of 
BoNT-induced neuroparalysis. The lifetime of the metalloprotease within 
the nerve terminal cytosol is the predominant, but not the only factor that 
contributes to the time of paralysis (Pantano & Montecucco, 2014; 
Shoemaker & Oyler, 2013). The time of paralysis varies with the 
vertebrate species, the activity of the affected muscle, the toxin dose and 
the BoNT serotype involved. In mice the duration of paralysis is in the 
following order (with the longest duration of action first): BoNT/A, /C, 
/B, /D, /F, /G, /E (Naumann et al., 2013). 
The pharmacologic potency, high specificity, and long duration of effect 
of BoNTs make these toxins remarkably effective therapeutic agents for 
the management of several disorders characterized by muscle 
hyperactivity. 
In the next chapter will be discussed the clinical and experimental use of 
botulinum neurotoxin.  
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Chapter 2 
BoNTs and neuropathic pain 
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The medical use of BoNTs as helpful drugs starts in the early 70s during 
the search for an alternative care to surgery for the treatment of 
strabismus. In those years several experiments on animals have 
demonstrated that low doses of BoNT/A produced the desired long-
lasting dose-dependent muscle weakening without any systemic toxicity 
(Scott et al., 1973). Based on these results, in 1979 FDA (Food and Drug 
Administration) permitted to test BoNT/A in humans for the treatment of 
strabismus. These tests successfully demonstrated the effectiveness of 
neurotoxin and the results were published in 1980 (Scott, 1980). With 
this publication BoNT/A was decreed as a ʽʽnovel therapeuticʼʼ and in 
1989 FDA approved the ʽʽAlan Scott's type A neurotoxin preparationʼʼ 
as Oculinum, later renamed Botox®. In the 80s other research groups 
tested the neurotoxin for treatment of blepharospasm and dystonia and, 
once again, the BoNT/A successes for these medical indications were 
reported (Brin et al., 1987; Tsui et al., 1985). Afterwards BoNT/A has 
been used for different human diseases characterized by hyperactivity of 
the colinergic neuromuscolar fibres such as multiple dystonias (e.g. 
cranial, cervical, laryngeal, limb, hand) (Brin et al., 1987; Tsui et al., 
1986), facial emispasm (Yoshimura et al., 1992), spasticity post stroke 
(Brashear et al., 2002), clubfoot (Ramachandran & Eastwood, 2006), 
infantile cerebral paralysis (Wasiak et al., 2004), and various other 
neurogenic conditions. During the use of BoNT/A for treatment of 
spasticity disorders it has been accidentally observed that pain associated 
with muscle spasms was significantly reduced to a level not ascribable to 
the simple reduction of muscle contracture (Brin et al., 1987). This 
observation, followed by intensive research, allowed in 2000 the FDA to 
approve the use of BoNT/A (Botox®) and BoNT/B (Myobloc®) for the 
treatment of abnormal head position and neck pain associated with 
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cervical dystonia (Abrams & Hallett, 2013). Subsequent studies, intent to 
understand the mechanism of action of BoNTs, have helped to determine 
that the neurotoxin, despite acting preferentially on nerve terminals 
between motor neurons and muscle fibers, can block the release of 
different neurotransmitters, including those involved in pain transmission 
(Arezzo, 2002; Cui et al., 2004; Park et al., 2015; Bittencourt da Silva et 
al., 2014; da Silva et al., 2014, 2015). These results have stimulated the 
study of the effects of BoNTs on the mechanism of pain and how and 
why BoNTs have relevant effects upon a variety of pain states, including 
neuropathic pain. 
Neuropathic Pain 
Generally, pain is divided into nociceptive and pathological pain. 
Nociceptive pain is caused by the sustained activation of peripheral 
nociceptors in response to peripheral tissue injury. The extent of 
nociceptive pain normally reflects the extent of tissue damage and when 
the damage heals it disappears. As opposed to nociceptive pain, 
pathological pain often depends on a chronic condition in which pain 
exceeds the extent of tissue damage. One type of chronic pain is 
neuropathic pain (NP), which is defined as ʽʽpain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system 
either at peripheral or central levelʼʼ (Haanpää et al., 2011). Diabetes, 
infection, nerve trauma and autoimmune conditions are examples of 
illnesses that may cause neuropathic pain. NP can occur spontaneously or 
can be evoked by a stimulus. It is described as burning, itching, lancing, 
and numbness but the symptoms that most characterize NP are two: 
hyperalgesia and allodynia (Intiso et al., 2015). Allodynia is related to a 
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condition in which a stimulus that normally does not cause pain becomes 
painful while hyperalgesia describes a state in which a stimulus that 
normally causes pain produces increased pain. The pathophysiological 
mechanisms underlying NP are not fully understood. Various hypotheses 
have been proposed including sensitization of nociceptors, abnormal 
ectopic excitability of neurons affected, loss of nociceptive control at the 
spinal level and CNS reorganization. All these conditions characterize 
the peripheral and central sensitization (Nickel et al., 2012).  
Harmful stimuli (mechanical, thermal or chemical), applied to the skin or 
underlying tissues, activate nociceptors that are constituted by the free 
endings of afferent nociceptive fibers (the unmyelinated C and 
myelinated Aδ fibers) (Costigan et al., 2009). Nociceptor activation 
causes, among others, the release of calcitonin gene-related peptide 
(CGRP) and substance P (SP) from nociceptive nerve endings. CGRP 
modulates the cholinergic system, facilitates glutamatergic transmission 
and induces vasodilation; SP acts on mast cells inducing the release of 
histamine and cytokines, which directly excite nociceptors. Inflammatory 
mediators, produced by inflamed or damaged tissue and by immune 
system cells, such as bradykinin, prostaglandins and other derivatives of 
arachidonic acid together with growth factors, neurotransmitters and 
excitatory substances, can also activate and sensitize nociceptors (Julius 
& Basbaum, 2001). Nociceptors sensitization, also called peripheral 
sensitization, is determined by a lowering of activation threshold of free 
endings of nociceptive fibers (this causes hyperalgesia), until arriving in 
the most intense cases to the spontaneous activation (ectopic impulse 
generation) with onset of pain in the absence of stimulus (Costigan et al., 
2009). Afferent nociceptive fibers, whose cell bodies are located in the 
dorsal root ganglia, convey the nerve impulses from periphery to the 
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dorsal horn of the spinal cord (lamina I-V). In the dorsal horns the 
majority of primary afferent fibers generates synapses with interneurons, 
whose axon remains entirely in the spinal cord and ramifies inside it. 
Here, the central endings of sensory fibers release glutamate and 
different neuropeptides including substance P, which increases and 
potentiates the action of glutamate (De Biasi & Rustioni, 1988). It was 
noted that as a result of persistent tissue damage, C fibers can discharge 
action potentials in a sustained and repeated manner. This causes a 
massive glutamate release and a sustained depolarization of dorsal horn 
neurons. In dorsal horn interneurons the excitatory amino acid glutamate 
determines the opening of ion channels type N-methyl-D-aspartate 
(NMDA) that produces an influx of extracellular Ca
2+
. The intracellular 
increase of Ca
2+
 induces the expression of c-fos, a protein believed to be 
involved in the transcriptional control of genes that encode a variety of 
neurotransmitters, their receptors, and neuropeptides, including 
enkephalin and dynorphin. Enkephalin typically produces antinociceptive 
effects, while dynorphin has direct excitatory effects on spinal projection 
neurons but may also produce inhibition via a negative feedback 
mechanism on dynorphin-containing neurons (Hunt et al., 1987; Dubner 
& Ruda, 1992; Coderre et al., 1993). Therefore, a persistent tissue 
damage can lead to long-term changes in excitability of the interneurons 
of the dorsal horn and so generate a central sensitization namely a ʽʽpain 
memoryʼʼ (Harden, 2005). Additional mechanism that contributes to the 
development of central sensitization is the loss of inhibitory control 
projecting to the superficial spinal cord dorsal horn. The spinal pain 
transmission system is under continuous inhibitory control generated by 
inhibitory interneurons, which release γ-aminobutyric acid (GABA), 
glycine, and endogenous opioids (enkephalins), and by descending 
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inhibitory pathways that release serotonin and norepinephrine (Harden, 
2005). Because this inhibition acts as a ʽʽspinal gateʼʼ for sensory 
information, reduced inhibition increases the activity of neurons of the 
dorsal horn and promotes the central sensitization genesis. It was also 
observed that partial nerve injury may cause GABAergic inhibitory 
interneuron apoptosis and degeneration of C fibers (Moore et al., 2002). 
In the spinal cord most of the opioid μ receptors are located on the 
presynaptic terminal of the fibers C. Therefore, the loss of these afferent 
fibres results in a failure to analgesic response to endogenous opioids, 
favoring the maintenance of pain states, and the loss of an important 
pharmacological approach to neuropathic pain (Dickenson, 1994). 
Pre-clinical and clinical use of BoNTs in the 
treatment of neuropathic pain 
Neuropathic pain is a debilitating condition for which there are few 
effective treatments which can also have significant side effects. BoNTs 
are used frequently to treat muscle hyperactivity but are emerging more 
and more evidence in support of its analgesic potential (Walsh, 2010; 
Luvisetto et al., 2015; Pavone & Luvisetto, 2010; Bittencourt da Silva et 
al., 2014; da Silva et al., 2014; Cairns & Gazerani, 2014). The majority 
of the studies have focused on the commercially available BoNT/A 
(Botox®, Xeomin®, Dysport®) and BoNT/B (Myobloc®) serotypes but 
only BoNT/A was better evaluated in pre-clinical and clinical studies on 
neuropathic pain.  
Table 2 summarizes the studies that have examined the effectiveness of 
BoNT/A and BoNT/B in peripheral neuropathic pain conditions. 
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Table 2. Pre-clinical and clinical studies that have examined the effectiveness of 
BoNT/A and BoNT/B in neuropathic pain conditions.(Adapted from Pellet et al., 2015). 
Neuropathic pain 
 Type of pain BoNT serotype References 
 
 
 
 
Pre-clinical 
studies 
(Rat/Mouse) 
 
Mononeuropathy 
(Nerve ligation and 
nerve transection) 
 
 
BoNT/A 
and 
BoNT/B 
 
(Park et al., 2006; Luvisetto et al., 
2007; Kitamura et al., 2009; Filipović 
et al., 2012; Huang et al., 2011; Park 
et al., 2015; Marinelli et al., 2010; 
Bach-Rojecky et al., 2005) 
 
 
Polyneuropathy 
(Chemotherapeutics, 
diabetes) 
 
BoNT/A 
and 
BoNT/B 
 
 
(Favre-Guilmard et al., 2009; Bach-
Rojecky et at., 2010; Park et al., 2015) 
 
 
 
 
 
 
Clinical studies 
(Human) 
 
Mononeuropathy 
(Peripheral nerve injury 
and 
trigeminal neuralgia) 
 
BoNT/A 
and 
BoNT/B 
 
 
(Ranoux et al, 2008 .; Borodic & 
Acquadro, 2002; Piovesan et al., 2005; 
Türk et al, 2005.; Bohluli et al., 2011; 
H. Wu et al., 2012; Zhang et al., 2014; 
Breuer et al., 2009) 
 
Polyneuropathy 
(Diabetic neuropathy) 
 
BoNT/A 
 
 
 
(Ghasemi et al., 2014; Yuan et al., 
2009; Jin et al., 2009; H. Wu et al., 
2012;) 
 
Chronic low back 
pain 
 
BoNT/A 
 
 
(Jabbari, 2008) 
 
Myofascial pain 
 
BoNT/A 
 
 
(De Carli et al., 2016; Cheshire et al., 
1994) 
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The analgesic effect of BoNTs:  
experimental evidence 
Many models of neuropathic pain are currently in use both in rats and 
mice to mimic human peripheral neuropathic conditions. 
Mononeuropathy can be generated by Spinal Nerve Ligation (SNL) (Kim 
& Chung, 1992) and Sciatic Nerve Transection (SNT) (Campbell & 
Meyer, 2006), which simulate the clinical conditions of the amputation. 
By Partial Nerve Ligation (PNL) is possible to reproduce a nerve damage 
trauma-induced (Seltzer et al., 1990) and with Chronic Constriction 
Injury (CCI) may be recreated the clinical conditions of the chronic nerve 
compression (Bennett & Xie, 1988). Polyneuropathy can be induced by 
chemotherapy (vinca alkaloids, platinum drugs) or by diabetes (Siau et 
al., 2006; Tesch & Allen, 2007). The effect of BoNT/A on neuropathic 
pain was first analyzed on the peripheral neuropathy induced by partial 
sciatic nerve transection in rats (Bach-Rojecky et al., 2005). In this study 
the authors observe that a single peripheral injection of BoNT/A was 
sufficient to reduce thermal and mechanical hyperalgesia. The 
antinociceptive effect started 5 days following BoNT/A injection and 
lasted at least 15 days. Subsequently Park et al. (2006) tested the 
analgesic efficacy of BoNT/A in rats subjected to spinal nerve ligation. 
The researchers found that peripherally administered BoNT/A reduces 
mechanical and cold allodynia in neuropathic animals. By using chronic 
constriction injury (CCI) of the sciatic nerve in mice and rats other 
authors found that a single non-toxic dose of BoNT/A into plantar 
surface of animals injured paws was sufficient to induce antiallodynic 
effects for at least 3 weeks (Luvisetto et al., 2007; Marinelli et al., 2010). 
These effects were evident 24 hours after BoNT/A injection and were 
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dose-dependent. Furthermore, if BoNT/A was injected contralaterally to 
the lesion, the antiallodynic effects were not observed, demonstrating the 
absence of a systemic diffusion of the toxin in these experimental 
conditions. Unilateral infraorbital nerve constriction (IoNC) is an animal 
model that induces trigeminal neuralgia. By using this pain model, 
Kitamura et al. (2009) found that intradermal injection of BoNT/A in the 
area of infraorbital branch of the trigeminal nerve alleviated trigeminal 
neurophaty in rats. Similar results were obtained by Filipovic and his 
coworkers (2012). The authors observe that a single unilateral BoNT/A 
injection reduced allodynia induced by infraorbital nerve constriction and 
the dural extravasation that accompanies it for more than two weeks. 
Favre-Guilmard's group investigated the effect of BoNT/A in paclitaxel-
induced peripheral neuropathy in rats (Favre-Guilmard et al., 2009). 
Paclitaxel treatment mimics the peripheral polyneuropathy induced by 
chemotherapy. The researchers observe that a single subplantar injection 
of BoNT/A produced a significant antihyperalgesic effect in the ipsi and 
contralateral injected paw of neuropathic animals 3 days after 
administration. In another study, animals become diabetic by a single 
intraperitoneal injection of streptozotocin were injected with BoNT/A 
either subcutaneously (Bach-Rojecky et al., 2010). As observed with 
paclitaxel treatment, also with this experimental pain model the authors 
demonstrate that BoNT/A reduced mechanical and thermal 
hypersensitivity not only on ipsilateral, but also on contralateral side. The 
antinociceptive effect started 5 days following BoNT/A injection and 
lasted at least 15 days. Due to the higher toxicity in mice and the 
resistance to the toxin in rats (Montecucco et al., 1994; Luvisetto et al., 
2003), the effect of BoNT/B on peripheral neuropathic pain only recently 
was analyzed. In this regard, Huang and colleagues (2011) wanted to 
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investigate the effects of intrathecal (IT) BoNT/B injection on spinal 
nerve ligation-induced tactile allodynia in mice. In this study, a single IT 
BoNT/B injection was administered and pain thresholds were assessed 
up to 15 days after BoNT/B injection. The analgesic effect of BoNT/B 
became evident within 6 hours after IT treatment and lasted for the next 
15 days. By observation of motor behavior, this experiment also revealed 
that the animals showed normal motor function and symmetrical 
ambulation and did not show signs of motor weakness. These results 
suggested a long-term alleviation of hyperalgesia by IT BoNT/B 
injection, as well as long-term dose-tolerability of the neurotoxin in 
mouse. A recent study described for the first time the effects of 
intraplantar BoNT/B administration on mono and polyneuropathies (Park 
et al., 2015). In this experiment mononeuropathy (MN) with ipsilateral 
tactile allodynia in mice is generated by physical injury to a peripheral 
nerve (L5 nerve ligation) whereas exposure to a chemotherapeutic agent 
(cisplatin) results in a polyneuropathy (PN) with persistent bilateral 
allodynia. On day 14, after the left L5 ligation for the MN, or day 15, 
after the initiation of the intraperitoneal cisplatin injection series for the 
PN, a single non-toxic dose of intraplantar BoNT/B was administered 
into the left hind paw. In this study the authors observed that BoNT/B 
injection prevented the allodynia in the ipsilateral but not in the 
contralateral paw in MN mice. Similarly, in the bilateral allodynia 
observed in the PN, the effect of the toxin was most evident in the paw 
ipsilateral to the intraplantar delivery. The authors emphasize the 
importance of the homolaterality antiallodynic effect of BoNT/B as it 
indicates that, as already observed with BoNT/A, the effects of 
intraplantar injection of the neurotoxin were not the result of a general 
systemic or contralateral spread of the treatment.  
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The analgesic effect of BoNTs:  
clinical evidence 
In parallel to pre-clinical studies, the effect of BoNTs on neuropathic 
pain was also analyzed in clinical trials.  
Ranoux' study has been the first double blind trial on the effect of 
BoNT/A in painful post-traumatic neuropathy (Ranoux et al., 2008). In 
this study, twenty-nine patients with focal painful neuropathies and 
mechanical allodynia received intradermal administration of BoNT/A 
into the painful area. The follow-up was performed at 4, 12 and 24 weeks 
after injections. BoNT/A treatment was associated with significant pain 
improvement from 2 weeks after the injection to 14 weeks. In particular, 
a reduction of the intensity of mechanical allodynia on the painful side, 
without alteration of the perception thresholds, were observed. These 
results indicated for the first time that BoNT/A may induce direct 
analgesic effects in patients with chronic neuropathic pain. Several 
studies concerned the use of BoNT/A for the treatment of trigeminal 
neuralgia (TN). In an open-label pilot study, Borodic & Acquadro (2002) 
evaluated the efficacy of multifocal BoNT/A injections for the treatment 
of patients with postsurgical pain syndromes, temporomandibular 
syndrome and idiopathic trigeminal neuralgia. 33 of 44 patients 
responded positively to treatment, including 8 of 11 patients with TN. 
The duration of beneficial effect ranged from 2 to 4 months. Thereafter 
other clinical studies have reported the same results also in patients 
refractory to classical medical treatments (Piovesan et al., 2005; Türk et 
al., 2005; Zúñiga et al., 2008; Bohluli et al., 2011). After positive 
outcomes from these studies, several double-blind and placebo-controlled 
trials were conducted (Wu et al., 2012; Zhang et al., 2014). In particular, 
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Zhang and coworkers (2014) treated 56 cases of classical TN with local 
multi-point injection of BoNT/A while 28 neuralgic patients received 
placebo. Follow-up visits were conducted every week after the injection, 
and the overall duration of the study for each patient was 8 weeks. 
BoNT/A significantly reduced pain intensity from the first week and the 
duration of beneficial effect was observed for all eight weeks. Another 
study investigated the effect of intradermal BoNT/A injections on pain 
symptoms of patients with diabetic neuropathic pain (Ghasemi et al., 
2014). In this randomized controlled, double-blind clinical trial study, 40 
diabetic patients with neuropathic pain in both feet were enrolled. 
Intradermal BoNT/A injections across dorsum of feets reduced burning, 
lancing, and numbness without causing side effects. Few years earlier, 
similar results had been obtained by Yuan et al. (2009). Another painful 
condition treated with BoNT/A is the phantom limb pain (PLP). Phantom 
limb pain and sensations are common in amputees; the pathophysiology 
is unclear and the treatment is difficult and often unsuccessful. Opioids 
are frequently used when non-narcotics failed, but are not effective in 
many cases. Jin et al. (2009) report a study on three patients, resistant to 
previous therapies, who were successfully treated with BoNT/A. In all 
three cases, the pain intensity was reduced significantly and no side 
effects were reported. The duration of response lasted up to 11 weeks. 
In 2012, Wu and colleagues (Wu et al., 2012) conducted the first 
randomized, double-blinded pilot study on PLP. 14 amputees with 
intractable PLP received BoNT/A injection. BoNT/A injection was 
compared to lidocaine in patients with PLP and residual limb pain (RLP). 
RLP was defined as a painful condition that could occur very quickly 
after amputation due to scar and neuroma formation. Each patient was 
evaluated at baseline and every month after the injection for 6 months. 
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Researchers found that both BoNT/A and lidocaine injections resulted in 
immediate improvements of RLP and pain tolerance. The treatment 
effect lasted for 6 months in both groups (Wu et al. 2012). The 
effectiveness of BoNT/A was also evaluated in the treatment of chronic 
back pain and on myofascial pain syndrome (Jabbari, 2008; De Carli et 
al., 2016; Cheshire et al., 1994). For both pathologies, BoNT/A has 
proven effective in reducing pain.  
As opposed to BoNT/A, only few studies have focused on clinical use of 
BoNT/B and of these the majority was concentrated on the therapeutic 
use the toxin in neurological disorder with muscular hyperactivity. Dry 
mouth is the most frequently reported side effect of BoNT/B in all the 
studies, even with very low doses and nausea, constipation, dysphagia 
and short efficacy have often been noted (Bentivoglio et al., 2015). In 
respect to the clinical use of BoNT/B on peripheral neuropathic pain, 
only one study is reported (Breuer et al., 2006). In this randomized, 
double-blinded pilot study the authors enroll 20 patients with carpal 
tunnel syndrome with associated hand pain to receive placebo or 
BoNT/B injections in three muscles anatomically attached to the carpal 
tunnel. The initial plan was to randomize the patients for each of the 
following treatments: placebo (normal saline solution); 2.500, 5.000 or 
7.500 units of BoNT/B. During the trial, however, the authors were 
obliged to unblind the treatment of two patients (they had received 7.500 
or 5.000 units of BoNT/B) due to adverse events occurred. The results of 
this experiment showed that the treatment with either BoNT/B or placebo 
decreases the hand pain. The maximum improvement occurred between 
weeks 6 and 9 of the trial. Significant decreases in pain were noted in 
both placebo and BoNT/B groups but there were no significant 
differences between the two groups. The authors conclude by affirming 
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that, despite BoNT/B is not dramatically superior to placebo for the relief 
of carpal tunnel syndrome symptoms, the similarity of improvements for 
both interventions suggests a strong placebo effect rather than a reduced 
effectiveness of treatment (Breuer et al., 2006; Singh, 2013).  
Mechanism-based evidence for the analgesic action 
of BoNT/A and BoNT/B 
With regard to the underlying pathophysiological mechanisms that 
operate in reducing pain, although several hypotheses have been 
suggested, the mechanisms of the analgesic effects of BoNTs remain 
unclear. A direct involvement of BoNTs in mechanisms involved in pain 
modulation was described by Cui et al. (2004) and Luvisetto et al. 
(2006), who analyzed the effects of BoNT/A and BoNT/B in formalin-
induced inflammation as an animal model of inflammatory pain. Cui and 
coworkers noticed that a single peripheral subcutaneous injection of 
BoNT/A, after formalin solution injection into one hindpaw of rat, was 
able to reduce licking activity during the second inflammatory phase, 
which reflects the activation of central sensitization processes. The 
reduction of licking activity was accompanied by the inhibition of 
peripheral release of glutamate into the injected paw and by a reduction 
of paw edema that is usually observed as a consequence of inflammatory 
processes. This latter effect suggested to the researcher that BoNT/A may 
reduce not only the release of glutamate, but also of SP and CGRP, two 
neuropeptides involved in plasma extravasation and vasodilation. The 
analgesic activity of BoNT/A was considered by Cui and coworkers as a 
consequence of inhibition of peripheral sensitization, resulting in an 
indirect reduction of central sensitization processes. Luvisetto et al. 
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(2006) confirmed these results and extended the analysis on 
inflammatory pain using two BoNTs serotypes (BoNT/A and BoNT/B) 
and two different routes of administration (intracerebroventricular and 
intraplantar). These authors prove that pre-treatment with BoNT/A was 
able to reduce the second phase of formalin independently from the route 
of administration and that the neurotoxin could act not only peripherally 
but also at the central level. On the contrary, BoNT/B did not reduce 
licking activity and, when centrally injected, had a hyperalgesic effect on 
the interphase of the formalin test, phase characterized by the lack of 
licking activity due to inhibitory descending pathways. These results 
indicated a different mechanism of action of BoNTs and suggested that 
the two serotypes were not interchangeable, an important point to take 
into account when evaluating BoNTs as pain pharmaceuticals (Cui et al., 
2004; Luvisetto et al., 2006). Previous in vitro experiments have already 
demonstrated that glutamatergic neurons are blocked by BoNT/A and 
BoNT/B while GABAergic neurons are blocked only by BoNT/B 
(McMahon et al., 1992; Frassoni et al., 2005; Verderio et al., 2004; 
Verderio et al., 2007). Considering the different effects of the two 
neurotoxins of different cell types, the effect of BoNT/B described by 
Luvisetto and coworkers (2006) on the interphase of the formalin test 
could be partially attributed to a block of GABA inhibition on the 
primary afferent fibers in spinal dorsal horn. Subsequent studies have 
also confirmed the hypothesis about the ability of BoNTs to interfere 
with the expression of substance P and calcitonin gene-related protein 
(CGRP), key mediators of neurogenic inflammation (Marino et al., 2014; 
Ramachandran et al., 2015; Hou et al., 2007; Lucioni et al., 2008; Meng 
et al., 2009). Different results about the analgesic effect of BoNT/B were 
published in the following years. In 2011, Yaksh et al (2011) showed that 
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a single IT injection of BoNT/B, 2 or 5 days prior of intraplantar 
formalin injection, reduces the release of substance P from spinal afferent 
nociceptors and reduces spinal neuronal activation and nociceptive 
behavior in mice. In addition, in mice with spinal nerve ligation, IT 
injection of BoNT/B decreases tactile allodynia within 6 hours after IT 
treatment and lasted for the next 15 days (Yaksh et al., 2011). This study 
provided an initial assessment of the ability of IT BoNT/B injections to 
regulate spinal nociceptive processing. Few years later the results were 
confirmed using intraplantar injections of BoNT/B in mice (Marino et al., 
2014). This experiment also showed that peripherally delivered BoNT/B 
is taken up at the peripheral afferent terminals and is transported in an 
active form to central afferent terminals where prevents the transmitter 
release. In the same years other studies demonstrated that BoNT/A can 
undergo, as well as an axonal migration, also a neuronal transcytosis 
(Restani et al., 2011, 2012; Matak et al., 2012; Antonucci et al., 2008; 
Marinelli et al., 2012). Marinelli and colleagues (2012) demonstrated that 
a single peripheral administration of BoNT/A in the paw of CCI mice 
was able not only to induce analgesic action but also to accelerate 
functional recovery through an acceleration of regenerative processes 
associated to the Schwann Cells proliferation. With the aim to better 
define the role of BoNT/A as an analgesic and to investigate the neural 
mechanisms involved, Mika et al. (2011) wanted to investigate the 
molecular changes that occur in DRG and spinal cord after CCI to the 
sciatic nerve in rats. The authors observed that peripheral administration 
of BoNT/A attenuates neuropathic pain-related behavior by modulating 
several proteins in DRG and spinal cord and by silencing microglia and 
macrophages in the same structures. The researchers suggest that the 
silence of microglia/macrophages after BoNT/A administration could be 
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secondary to the inhibition of neuronal activity and that this decrease in 
neuroimmune interactions could be the key to the long-lasting BoNT/A 
effect on neuropathic pain. Despite Mika et al. (2011) observations, and 
although the involvement of SNARE proteins in the release of mediators 
from macrophages has been demonstrated (Stow et al., 2006), the direct 
effect of BoNT/A and BoNT/B on this release thus far has not been 
adequately understood, as well as it was not understood the exact 
mechanism responsible for the analgesic effects of BoNT/A and 
BoNT/B. 
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Aim 
Therapeutic use of botulinum neurotoxins is well established and is 
continuously expanding. In clinical practice, BoNT/A has been widely 
used to treat many pathological conditions characterized by autonomic 
overactivity. Although much is known about the action of BoNTs on the 
peripheral system, increasing evidence has demonstrated several effects 
also at the central level. Current data suggest that BoNTs, given locally 
into peripheral tissues, alter nociceptive processing initiated by 
inflammation or nerve injury. This demonstration has recently allowed 
the use of BoNT/A as a novel treatment option for a variety of pain 
syndromes including neuropathic pain, pathological pain condition for 
which no definitive treatments are available. In clinical practice it was 
observed that an increasing number of patients become non-responding 
to BoNT/A, in particular when repetitive injections were done. The 
absence of clinical response could be related to an immune response 
caused by the production of specific anti-BoNT/A antibodies. It was 
suggested that subjects who become less and less sensitive to BoNT/A 
could be treated with alternative BoNT serotypes: BoNT/B was proposed 
as a potential therapeutic option to BoNT/A. However, nowadays, the 
cellular and molecular pharmacology and mechanism of action of 
different BoNT serotypes is still not fully understood. Therefore, to avoid 
errors and ensure the therapeutic efficacy and safety of treatment, it 
becomes imperative to compare the mechanism of action adopted by the 
two neurotoxins, and if necessary to highlight their differences.  
In this regard, the general purpose of my PhD project has been to assess 
the effect of BoNT/B on neuropathic pain. To this aim, mice made 
neuropathic by Chronic Constriction Injury (CCI) of sciatic nerve, were 
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injected with a single dose of BoNT/B (5 or 7.5 pg) into the injured hind 
paw. The time course of the neuropathy was observed for 101 days and 
the effect of the neurotoxin on both pain and functional recovery was 
evaluated. For a qualitative analysis of structural alterations and for a 
comparison with functional data, immunofluorescence (IF) experiments 
were associated to behavioral tests. By means of the investigative 
technique of IF, carried out on the sciatic nerve and on the dorsal horn of 
the spinal cord, we wanted to analyze the expression of several neuronal 
and glial markers associated with neurodegenerative and regenerative 
processes. In particular, in order to observe structural changes in 
damaged nerve, we analyzed the expression of NF200, marker of neurons 
intermediate filaments, P0 and PMP22, markers of peripheral myelin 
proteins. Moreover, we analyzed the expression of markers (GFAP, 
S100β) of Schwann Cells (SCs), and of SCs proliferation, which 
represent an important event promoting axon regeneration, by studying 
the co-expression of a SCs marker with the Cdc2 proliferation marker. 
The study of the expression of CC1 (marker of mast cells) and CD11b 
(marker of macrophages) gave us the opportunity to investigate the 
activation of immune cells, after the nerve damage. In spinal cord, to 
observe microglial cells, members of the monocyte/macrophage family, 
and their activation, we examined the coexpression of Cd11b and p-p38 
markers on ipsilateral-side of dorsal and ventral horn. Microglial 
recruitment and activation in dorsal and ventral horn is accompanied by 
proliferation and activation of astrocytes in the ipsilateral-side of spinal 
cord. Together with microglia astrocytes play a critical role in chronic 
pain sensitization and their activation is correlated with chronic pain 
behaviors (Wang et al., 2009; Liu et al., 2012). In order to observe 
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astrocytes and their activation we used GFAP and p-p38 markers on 
dorsal and ventral horn of spinal cord.  
Materials and methods 
Animals 
CD1 male mice (Charles River, Como, Italy) were used in the present 
study. Upon arrival, the animals were housed in groups of four in 
standard breeding cages (21cm x 21cm x 12 cm) placed in a rearing room 
at a constant temperature (22±1 
°
C) under diurnal conditions (light–dark: 
08:00–20:00), with food and water ad libitum. At the time of surgery, 
they were approximately 12 weeks old and their weights ranged from 40 
to 45g. The experiments were carried out between 10:00 and 14:00 h. 
Testing was performed blind as for treatment group to which each 
subject belonged. All procedures were in strict accordance with the 
Italian National law (DLGs n.26, 04/03/2014, application of the 
European Communities Council Directive 2010/63/UE) on care and 
handling of the animals, with the Institute’s Animal Research Committee 
(Krakow, Poland) and with the guidelines of the Committee for Research 
and Ethical Issues of IASP (Zimmermann, 1983). 
Surgical procedure 
Following the procedure originally proposed by Bennett and Xie 
(Bennett & Xie, 1988) adapted for mice, the Chronic Constriction Injury 
(CCI) of sciatic nerve was used as model of peripheral nerve injury that 
can evoke neuropathic pain symptoms.  
Surgery was performed under anesthesia induced by intraperitoneal 
injection (ip) of a mixture of ketamine (100 mg/kg) and xylazine (5 
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mg/kg) purchased from Sigma-Aldrich (St. Louis, MO). CCI was 
obtained by three unilateral ligatures of sciatic nerve. The middle third of 
the right sciatic nerve was exposed through a 1.5 cm longitudinal skin 
incision. Three ligatures (7-0 prolene, Ethicon) were tied loosely around 
the nerve. The wound was then closed with silk suture (4-0 vicryl, 
Ethicon) and the mouse was allowed to recover in a heated cage until all 
reflexes were normal. The injured and uninjured hindpaws were named 
as ipsilateral and contralateral hindpaws, respectively. To verify the 
occurrence of neuropathy, behavioral measurements were made on days 
3, 4 and 5 after CCI. Only neuropathic mice were included into the study. 
Drugs and peripheral injections 
BoNTs, isolated and purified, (Rossetto et al., 1992; Schantz & Johnson, 
1992), were a kind gift from Prof. C. Montecucco and Prof. O. Rossetto 
(University of Padova). The toxins were freezed in liquid nitrogen and 
stored at −80 °C in 10 mM Na HEPES, 150 mM NaCl, pH 7.2. Stock 
solutions of purified 150 kDa di-chain molecule of BoNT/A and BoNT/B 
were tested for activity in the ex vivo mouse hemidiagphram model and 
in the in vitro cleavage of SNAP-25 and VAMP/synaptobrevin. 
Injectable solutions of BoNTs were freshly made by dilution in saline 
(0.9% NaCl). BoNTs or vehicle injections were performed 5 days after 
CCI. For injections, a volume of 20 μl of either saline (0.9% NaCl) or 
selected BoNT solutions (BoNT/A: 15 pg/mouse; BoNT/B: 5 and 7.5 
pg/mouse) was subcutaneously (sc) injected into plantar surface of the 
injured hindpaw of mice using a microsyringe equipped with a 26 gauge 
needle. Dose of BoNT/A (15 pg/paw) was chosen on the basis of 
neurotoxicity and previous studies (LD50: 0.5–1.0 x 10
-6
 mg/kg) 
(Luvisetto et al., 2003, 2004, 2006; Marinelli et al., 2010). Dose of 
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BoNT/B (5 and 7.5 pg/paw) were chosen on the basis of preclinical 
studies on the safety margins of intramuscular injection of BoNTs in 
mice (Aoki, 2001). These studies show that BoNT/B subcutaneously 
administered into paw of mice is more toxic than BoNT/A, therefore, 
concentrations of BoNT/B higher than 7.5 pg/paw were not tested. The 
doses of BoNT/A and BoNT /B used in this experiment are the maximal 
effective doses that can be peripherally injected in mice without causing 
side effects including neuroparalysis and alteration of spontaneous 
locomotor activity.  
Experimental groups 
On day 3 post-CCI, mice were randomly assigned to different 
experimental groups. Behavioral investigation was conducted on three 
groups of animals two of which treated with two different doses of 
BoNT/B (5 and 7.5 pg/paw) and the third was used as control group. 
Regarding the IF analysis this was carried out on the sciatic nerve 
sections of four experimental groups: naive, CCI-saline, CC-BoNT/A 15 
pg and CCI-BoNT/B 7.5 pg/paw injected animals. For spinal cord IF 
were considered only naive and CCI-BoNT/B 7.5 pg/paw treated mice 
because data on CCI-BoNT/A 15 pg injected animals had already been 
published by our laboratory (table 3 shows the total number of mice 
assigned to behavioral tests and biochemical assay). 
To verify the occurrence of neuropathy, behavioral measurements were 
made on days 3, 4 and 5 after CCI. BoNTs or saline were injected into 
the injured hindpaws intraplantar (i.pl.) surface of mice on day 5, 2 hours 
after behavioral measurement. All groups of animals were examined for 
mechanical nociceptive thresholds, weight distribution, footprint walking 
tracks and measurement of sciatic static index (SSI). With the exception 
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of the animals sacrificed on day 7 post-CCI for IF analysis, all mice were 
tested until the day 101. 
 
Behavioral tests 
 
Number of mice 
 
Day of test 
 
CCI-BoNT/B 5 pg/paw 
(20μl) 
 
N=10 
 
From day 3 until day 101 
 
CCI-BoNT/B 7.5 pg/paw 
(20μl) 
 
N=10 
 
From day 3 until day 101 
 
CCI-Saline  
(20μl) 
 
N=10 
 
From day 3 until day 101 
 
Immunofluorescence 
(IF) analysis  
 Day of sacrifice 
to perform biochemical 
assay 
 
CCI-BoNT/B 7.5 pg/paw 
(20μl) 
 
N=3 
 
Day 7 post-CCI 
 
CCI-BoNT/A 15 pg/paw 
(20μl) 
 
N=3 
 
Day 7 post-CCI 
 
CCI-Saline 
 (20μl) 
 
N=3 
 
Day 7 post-CCI 
 
Naive 
(no CCI/injection) 
 
N=3 
 
Day 7 post-CCI 
 
Table 3. Total number of mice assigned to behavioral tests and biochemical assay. 
59 
 
Behavioral tests 
Measurement of mechanical nociceptive threshold 
The onset of CCI-induced neuropathy was assessed by measuring the 
threshold of both hindpaws to normally non-noxious punctuate 
mechanical stimuli. The hindpaw nociceptive threshold, measured by an 
automatic von Frey apparatus (Dynamic Plantar Aesthesiometer, Ugo 
Basile, Italy), was expressed as the force (in grams) at which mice 
withdrew their paws in response to the mechanical stimulus. For 
habituation, mice were placed in plastic cages with a wire net floor 5 
minutes before the experiment. The mechanical stimulus was applied to 
the mid-plantar surface of the hindpaw to induce a slight pressure to the 
skin. At each testing day, ipsi- and contra-lateral withdrawal thresholds 
were taken as mean of three consecutive measurements per paw with 10 
seconds interval between each measurement. 
Measurement of weight bearing 
Weight bearing on the two hindlimbs was determined by incapacitance 
test (Linton Instrumentation, Norfolk, UK). The apparatus used was 
adapted for mice with a strain gauge/amplifier resolution of 0.03 grams 
and a strain gauge/amplifier accuracy of 0.1 grams. Mice were carefully 
placed in an angled plexiglas chamber positioned with hindpaws on the 
two separate force plates. Care was taken to ensure that the animal 
weight was directed onto the force plates and not dissipated through the 
walls of the chamber. The force exerted by each hindlimb (measured in 
grams) was automatically averaged over a 5 seconds period and, for each 
animal, measurement was repeated three times with 5 minutes interval. 
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According to Helyes et al. (2010), the weight percent distributed onto the 
ipsilateral hindlimb was calculated by the equation:  
[ipsilateral weight/(ipsilateral weight + contralateral weight)] x 100. 
Walking track analysis and measurement of sciatic 
static index 
Evaluation of functional recovery was determined using the walking 
track analysis described by Inserra et al. (1998) and Varejão et al. (2001). 
The gradual recovery of the paw functionality was monitored through the 
analysis of individual free-walking patterns and by measuring several 
footprint parameters to calculate the sciatic static index (SSI). Footprints 
were recorded by dipping the mouse hindpaws in black ink and having 
them to freely walk along a Perspex runaway corridor (15 x 5 x 50 cm) 
lined with white paper (Dijkstra et al., 2000). Mice were tested from day 
3 to day 101 post-CCI and, for each mouse, the footprint parameters were 
calculated from at least five footprints recorded on three different 
walking track runaways. The SSI was evaluated using the formula 
proposed by Baptista et al. (2007), calculated considering two 
parameters: the 1st–5th toe spread (TS) and the distance between the tip 
of the third toe and the most posterior aspect of the paw (paw length 
(PL)). These variables were measured and entered into the equation: 
SSI=+101.3x(ITS-CTS)/CTS-54.03x(IPL-CPL) /CPL-9.5 
where ITS and CTS are the ipsilateral and contralateral toe spreads, while 
IPL and CPL are the ipsilateral and contralateral paw lengths, 
respectively. Based on the equation, a value of SSI close to 0 corresponds 
to normal function while a value of -100 is equivalent to complete 
functional loss. 
61 
 
Biochemical assay 
Sciatic nerve and Spinal cord immunohistochemistry 
7 days post-CCI, mice were anaesthetized with chloral hydrate (500 
mg/kg i.p.; Sigma-Aldrich, Italy) and the lesioned part of the ipsilateral 
sciatic nerve including ligatures were removed immediately before the 
perfusion and kept in immersion for 48 hours in paraformaldehyde (PFA 
(Sigma-Aldrich, Italy) 4% in 0.1 M phosphate-buffer saline (PBS, 
Sigma-Aldrich, Italy), pH 7.2, at room temperature. Trans-cardiac 
perfusion was performed with 100 ml saline, followed by 100 ml of PFA. 
After the perfusion, the entire spinal cord of each animal was removed 
and kept in PFA for 24 hours. Both nerves and spinal cord, after 
cryoprotection with solution of 30% (w/v) sucrose in PBS, were then 
stored at -80 °C until the sectioning. 
Longitudinal sections (25 μm thick) of D7/CCI-sciatic nerves segment 
including the portion with ligature were cut on cryostat microtome and 
mounted directly on slides. 
For IF staining, sciatic nerves sections were washed three times in PBS 
and then incubated overnight in Triton (Sigma-Aldrich, Italy) 0.3% in 
PBS, with different primary antibodies (see table 4): 
- rabbit anti-VAMP2 (polyclonal, 1:100, Abcam)  
- mouse anti-GFAP (monoclonal, 1:100, Sigma-Aldrich) 
- rabbit anti-PMP22 (polyclonal, 1:100, Sigma-Aldrich) 
- chicken anti-P0 (polyclonal, 1:100, Millipore) 
- rabbit anti-Neurofilament 200 (polyclonal, 1:100, Sigma-Aldrich) 
- mouse anti-S100β (polyclonal, 1:100, Sigma-Aldrich) 
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- rabbit anti-Cdc2 (polyclonal,1:100, Calbiochem) 
- rat anti-CD11b (monoclonal, 1:100, Biorad)  
- mouse anti-CC1 (monoclonal, 1:100, Santa Cruz)  
Afterwards, after three times washing with PBS, sections were incubated, 
for 2 hours at room temperature, in Triton with secondary antibodies : 
- donkey anti-mouse fluorescein-conjugated (FITC, 1:100, Jackson 
ImmunoResearch); 
- goat anti-rabbit fluorescein-conjugated (FITC, 1:100, Santa Cruz); 
- goat anti-rabbit rhodamine-conjugated (TRITC, 1:100, Jackson 
ImmunoResearch);  
- donkey anti-chicken rhodamine-conjugated (TRITC, 1:100, Jackson 
ImmunoResearch). 
Finally, the sections were and then incubated in with the nuclear marker 
bisbenzimide, DNA-fluorochrome (Hoechst 33258, 1:1000, Sigma-
Aldrich) in PBS for 5 minutes, washed again three times in PBS and 
closed with glycerol/PBS 3:1 mounting medium and coverslipped. 
For spinal cord, transverse sections (40 μm thick) of L4/L5 spinal cord 
segment were cut on a cryostat microtome and collected in PBS for free-
floating double IF procedures. Ipsilateral and contralateral side of 
sections were recognized by marking the spinal cord with a notch on the 
contralateral side before mounting spinal cord trunk on the chuck of the 
cryostat. Spinal cord sections were first incubated overnight in Triton 
with different primary antibodies (see table4): 
- mouse anti-GFAP (monoclonal, 1:100, Sigma-Aldrich)  
- rat anti-CD11b (monoclonal, 1:100, Biorad)  
- rabbit anti-p-p38 (polyclonal, 1:100, Santa Cruz). 
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Afterwards, the sections were washed three times in PBS and were 
incubated for 2 hours at room temperature in Triton with secondary 
antibodies: 
- donkey anti-mouse fluorescein-conjugated (FITC, 1:100, Jackson 
ImmunoResearch); 
- donkey anti-rat fluorescein-conjugated (FITC, 1:100, Jackson 
ImmunoResearch); 
- goat anti-rabbit rhodamine-conjugated (TRITC, 1:100, Jackson 
ImmunoResearch).  
Finally, the sections were washed three times in PBS, incubated in PBS 
with the nuclear marker Hoechst 33258, (1:1000), for 5 minutes, washed 
again and mounted on slides, air dried and cover slipped with 
glycerol/PBS 3:1 mounting medium.  
To exclude non-specific signals of secondary antibodies and to ensure 
optimal results, control sections have been stained with secondary 
antibody alone, which did not show appreciable staining (data not 
shown). 
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Tissue Antibody Target 
Nerve  
VAMP2 
Isoform 2 of VAMP 
protein 
  
GFAP 
Dedifferentiated 
nonmyelinating  
Schwann Cells 
  
PMP22 and P0 
Peripheral myelin 
proteins 
  
Neurofilament 200 
Neurons intermediate 
filaments 
  
S100 
Dedifferentiated 
myelinating  Schwann 
Cells 
  
Cdc2 
Proliferanting Schwann 
Cells 
  
CD11b 
Polymorphonuclear 
Cells, monocytes and 
NK Cells 
  
CC1 
Mast Cells Chymase 
Spinal cord  
GFAP 
Astrocytes 
  
CD11b 
Microglia 
  
p-p38 
Activated Cells 
 
Table 4. Tissue and antibodies with their target. 
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Three animals per group were considered and three sections per animal 
of sciatic nerve and spinal cord were randomly selected and analyzed by 
experimenters blinded as to the treatment groups. Low (10x) 
magnification images of spinal cord sections and High (63x) 
magnification images of spinal cord and sciatic nerve of different 
sections were captured, using fixed parameters, by laser scanning 
confocal microscopy (TCS SP5 microscope, Leica Microsystem) 
connected to digital camera diagnostic instruments operated by I.A.S. 
software (Delta Systems, Italy). Since the part of the injured sciatic nerve 
close to the neural body did not show differences compared to the control 
sciatic nerve, only the part of nerve including the ligature was used. In 
sciatic nerve sections, the analysis of IF staining (in term of emitted 
fluorescence), was performed by using the ImageJ software (version 
1.41, National Institutes of Health, USA). The fluorescence was 
quantified with RGB (red, green, blue) method, which uses brightness 
values for calculation (Fu et al., 2016). The number and emitted 
fluorescence of IF cells was automatically analyzed for each one of three 
nerve sections. Afterwards, the mean for each group of mice was 
calculated. For production of figures, brightness and contrast of images 
were adjusted by taking care to leave a light tissue fluorescence 
background to help visual appreciation of the lowest fluorescence 
intensity features and comparison among different experimental groups.  
In spinal cord sections, to quantify positive glial cells immunoreactivity 
(IR), images of the ipsilateral side of the dorsal horn (medial portion of 
laminae I–IV) and ventral horn (dorsolateral column, lamina IX) for each 
one of three spinal cord sections was examined. Identification of laminae 
areas was helped by Hoechst staining of cells nuclei. Quantification was 
performed by using the ImageJ software. Image contrast was adjusted 
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such that the background level just disappeared and the cell bodies and 
processes appeared without boundaries; the same cutoff level was used 
for all images. For analysis of labeling of GFAP or CD11b positive IR-
cells and their colocalization with p-p38, the number of positive IR cells 
was quantified for each one of the three spinal cord sections. 
Subsequently, the mean for each group of mice was calculated.  
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Results 
 
Behavioral Effects of BoNT/B on Neuropathic Pain 
Effects of BoNT/B on mechanical nociceptive threshold 
The unilateral ligature of the sciatic nerve induces mechanical allodynia 
in the hindpaw ipsilateral to the ligature. To determine if the treatment 
with BoNT/B is analgesic, we analyzed the effect of the toxin on 
mechanical nociceptive threshold in neuropathic mice.  
The withdrawal thresholds, of both the right and left hindpaw, was 
expressed as the force (in grams) at which mice withdrew their paw in 
response to the mechanical stimulus. Figure 7 shows that, after CCI, the 
mechanical nociceptive threshold decreased in CCI-saline injected mice 
around 50% in the ipsilateral compared to contralateral hind paw. 
Animals withdrew their ipsilateral paw after very low stimuli (6 grams), 
which did not evoke reaction in contralateral paw, therefore, we 
considered the ipsilateral response as allodynia. In CCI-saline treated 
mice, a robust ipsilateral allodynia was maintained for at least 50 days 
and, even if reduced, it was still present after 3 months, being the 
mechanical thresholds always different from those of contralateral paw. 
On the contrary, a single i.pl. injection of 5 or 7.5 pg/paw of BoNT/B in 
CCI-mice clearly antagonizes ipsilateral allodynia, as indicated by a net 
enhancement of the withdrawal threshold, with a recovery of 30%, 
corresponding to 80% of the value of the contralateral paw. In the CCI-
BoNT/B treated groups the strong antiallodynic effect of the toxin was 
observed from the day after the injection and persisted for a very long 
time (see figure 7). Two-way ANOVA for repeated measures showed a 
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significant main effect for treatment (F2,27 =10.941; p˂0.0003), days 
(F17,459 =68.739; p˂0.0001) and treatment x days interaction (F34,459 
=7.031; p˂0.0001) for mechanical threshold of ipsilateral hindpaws. For 
contralateral hindpaws only a main effect for days was observed (F17,459 
=1.7111; p=0.0369). Posthoc comparisons between CCI-saline and 5 
pg/paw CCI-BoNT/B injected mice showed a significant effect from the 
day 6 (the day after the injection) till day 31 while the dose of 7.5 pg/paw 
of BoNT/B resulted significantly different from CCI-saline treated mice 
till day 41 (Tukey-Kramer, p˂0.05). 
Additional Two-way ANOVAs for repeated measures between ipsi and 
contralateral hindpaws indicated a strong significant main effect in the 
following experimental groups: 
- CCI-saline mice: treatment (F1,18 =200.301; p˂0.0001), days (F17,306 
=13.299; p˂0.0001), treatment x days (F17,306 =16.585; p˂0.0001); 
- CCI-BoNT/B 5 pg/paw mice: treatment (F1,18 =106.817; p˂0.0001), 
days (F17,306 =15.155; p˂0.0001), treatment x days (F 17,306 =8.933; 
p˂0.0001); 
- CCI-BoNT/B 7.5 pg/paw mice: treatment (F1,18 =121.787; p˂0.0001), 
days (F17,306 =10.893; p˂0.0001), treatment x days (F 17,306 =12.198; 
p˂0.0001). 
Posthoc comparisons showed that, for all experimental groups, the 
withdrawal threshold of the ipsilateral hindpaw was always significantly 
different from the withdrawal threshold of contralateral hindpaw (Tukey-
Kramer, p˂0.05). Overall these data indicate a strong analgesic effect of 
the toxin that persists for at least 30 days. The analgesic effect of 
BoNT/B is similar for both doses, but its action in animals treated with 
the higher dose is long-lasting. In CCI-BoNT/B injected mice, 
mechanical allodynia in the ipsilateral hindpaw is reduced compared to 
69 
 
the CCI-saline treated animals, however, as for the control group, any 
BoNT/B group reaches the value of the uninjured contralateral paw (see 
figure 7). 
 
 
 
 
 
 
 
 
 
Figure7. Effects of a single injection into hind paw ipsilateral to the injury of saline (  
ipsi,  contra), BoNT/B 5 pg/paw (.  ipsi,  contra) and BoNT/B 7.5 pg/paw (  ipsi,  
contra) on mechanical allodynia. In CCI-BoNT/B injected groups the strong 
antiallodynic effect of the toxin is observed starting from the day after the injection and 
persists for a very long time (***p˂0.0001).  
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Effects of BoNT/B on functional recovery  
Weight bearing on the two hindlimbs  
The weight bearing value on the two hindlimbs, expressed by the ratio: 
ipsi/(ipsi+contra), was determined by an incapacitance test. The value of 
50% indicates an equal weight distribution between ipsilateral and 
contralateral hindlimbs. As shown in figure 8, just after CCI, in all 
experimental groups the weight distribution on the two hindlimbs was 
altered (weight bearing value ˂50). The graph indicates that in all animal 
groups there was a slow but not complete functional recovery over time 
and that the animals injected with both doses of the toxin showed no 
difference compared to control animals (Two-way ANOVA for repeated 
measures: treatment F2,27 =1.013; p=0.3765; days F17,459 =5.341; 
p˂0.0001; treatment x days F34,459 =1.226; p=0.1824). 
These results indicate that BoNT/B, both at low and high doses, has no 
effect on functional recovery.  
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Figure 8. Effects of a single injection into hind paw ipsilateral to the injury of saline  
( ), BoNT/B 5 pg/paw ( ) and BoNT/B 7.5 pg/paw ( ) on weight bearing. CCI-
animals injected with both doses of the toxin did not show difference compared to CCI-
saline treated group. The graph indicates that in all animal groups there was a slow but 
not complete functional recovery over time. 
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Walking track analysis  
A second evaluation of functional recovery was conducted using the 
walking track analysis by foot print test. Figure 9.1 shows a 
representative example of hind paws' walking pattern taken from a naive 
mouse. The gradual functional recovery of the animals was monitored 
measuring the sciatic static index (SSI) were a value of SSI close to 0 
corresponds to normal function while a value of -100 is equivalent to 
complete functional loss. Figure 10 shows the trend of functional 
recovery of animals over time. All experimental groups manifested a 
severe impairment of motor function as revealed by SSI values, around 
80, till day 32, then they showed a slow but not complete functional 
recovery. Moreover, animals with both doses of the toxin did not show 
improvement compared to CCI-saline injected animals, rather their 
performance was even reduced. Two-way ANOVA for repeated 
measures showed a significant main effect for days (F9,243 =32.786; 
p˂0.0001) and for treatment x days (F9,243 =2.867; p=0.0001). 
Posthoc comparisons between saline and 5 pg/paw BoNT/B treated mice 
showed a significant main effect from the day 62 to day 82 while the 
dose of 7.5 pg/paw of BoNT/B resulted significantly different from day 
42 to day 82 (Tukey-Kramer, p˂0.05), probably because the lower 
variability of the higher dose. 
These results indicate that BoNT/B slowed the functional recovery of 
mice. This slowdown appeared to be dose-dependent, in fact, the animals 
treated with the higher dose of BoNT/B expressed more negative values 
respect to CCI-saline injected animals for a longer period. At day 92, 
when probably the negative effect of the toxin disappeared, animals 
treated with BoNT/B returned to take SSI values similar to those of CCI-
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saline injected animals although at day 101 these still show clear signs of 
atrophy of the injured paw (Fig. 9.2). 
 
 
Figure 9.1. Rappresentative examples of foot print test. 9.2. At day 101 post-CCI 
BoNT/B injected mice still show clear signs of atrophy of the injured paw compared to 
CCI-saline treated animals. 
 
 
Figure 10. Effects of a single injection into hind paw ipsilateral to the injury of saline 
( ), BoNT/B 5 pg/paw ( ) and BoNT/B 7.5 pg/paw ( ) on SSI. BoNT/B slows 
functional recovery of mice. This slowdown appears to be dose-dependent, animals 
treated with the higher dose of BoNT/B expressed more negative values respect to the 
CCI-saline injected animals for a longer period (*p˂0.05). 
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Immunohistochemistry analysis  
Effect of BoNT/A and BoNT/B on sciatic nerve after CCI 
In the first part of our study we wanted to verify the presence of the 
target of BoNT/B on the nerve. Figure 11 shows immunofluorescence 
(IF) images of sciatic nerve section of naive, D7/CCI-saline and D7/CCI-
BoNT/B 7.5 pg/paw injected mice after incubation with rabbit polyclonal 
antibodies to VAMP2. As already demonstrated in rat (Jacobsson et al., 
1998), in naive animals VAMP2 was not detectable whereas VAMP2 
was present in CCI-mice. It has been suggested that the increased 
expression of VAMP2 in injured nerve stimulates the autocrine secretion 
of neurotrophins by motor neurons and increases the release of 
neuropeptides involved in regenerative processes (Jacobsson et al., 
1998). 
 
 
 
 
 
 
 
 
 
Figure 11. In naive animals no detectable VAMP2 has been seen whereas VAMP2 is 
present in CCI-mice. Scale bar: 25 μm. 
 
The injury caused by CCI determines structural changes in damaged 
nerve, induces the recall and activation of immune cells and promotes the 
synthesis of proteins necessary to support the subsequent axonal 
regeneration. Changes in the nerve at the site of injury begin almost 
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immediately. After axonal injury, the distal portion of the nerve 
undergoes progressive degeneration due to a series of events that induce  
the degradation of cytoskeletal proteins. The distal segment degeneration 
process is known as Wallerian Degeneration (WD) (Röyttä et al., 1987). 
To be able to observe the cytoskeleton of the nerve fibers we incubated 
sections of naive, D7/CCI-saline, D7/CCI-BoNT/A 15 pg/paw and 
D7/CCI-BoNT/B 7.5 pg/paw treated mice with rabbit polyclonal 
antibodies for Neurofilament-200 (NF200), marker of neurons 
intermediate filaments (figure 12). 
 
 
Figure 12. In naive animals the structure of the tissue is more uniform and compact 
than in CCI-mice. Scale bar: 25 μm. 
 
As shown by figure 12, naive animals present a more uniform and 
compact structure of the tissue while in CCI-mice, 7 days after injury, the 
tissue appears disjointed and broken up. As the axon disappears, 
Schwann Cells (SC), having lost axonal contact, are able to isolate small 
whorls of myelin and generate characteristic ovoids containing 
fragmented myelin. SCs play a key role in the breakdown of the myelin 
sheath and in the clearance of its debris. The loss of axon–SC contact is a 
signal causing the SCs proliferation, an important event that promotes the 
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axon regeneration. During proliferation, myelinating and nonmyelinating 
SCs change their phenotype from differentiated to dedifferentiated cells 
and this phenotypic switch is associated with down-regulation of the 
myelin-associated genes (e.g., P0, PMP22) and up-regulation of the 
regeneration-associated genes (e.g., neurotrophins and adhesion 
molecules) (Dubový, 2011). Figure 13 and 15 show IF double-staining in 
sciatic nerve section of naive, D7/CCI-saline, D7/CCI-BoNT/A and 
D7/CCI-BoNT/B injected mice. In figure 13.A, the double-staining is for 
GFAP (green), marker of dedifferentiated nonmyelinating SCs, and P0 
(red), marker of a major peripheral myelin protein (P0 represents roughly 
half of the total of the peripheral myelin). Low levels of green 
fluorescence, emitted from GFAP, were detected in naive mice. After 
nerve lesion, GFAP expression is upregulated and this upregulation is 
visible one day after injury, increases at 3-5 days and decreases slightly 
at 7 days (Berg et al., 2013). According, at day 7 post-surgery, our results 
showed an increased expression of GFAP in CCI-saline treated mice 
compared to naive animals. One-way ANOVA showed a significant main 
effect for treatment (F3,68 =16.591; p˂0.0001). Posthoc comparisons 
showed a significant effect between CCI-saline and naive, CCI-saline 
and CCI-BoNT/A, CCI-BoNT/A and naive, CCI-BoNT/A and CCI-
BoNT/B treated animals (Fisher’s PLSD analysis p˂0.05). Instead, 
animals treated with BoNT/B did not show differences in comparison 
either with naive or CCI-saline injected animals (figure 13.B). 
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Figure 13.A. Representative examples of IF images showing the expression of GFAP 
(green) and P0 (red) in sciatic nerve sections taken from naive, CCI-saline, CCI-
BoNT/A and CCI-BoNT/B treated mice. 13.B. Strong increase expression of GFAP is 
observed in CCI-BoNT/A injected mice. (**p˂0.001;***p˂0.0001 vs naive;°°p<0.001 
vs saline; ###p<0.0001 vs BoNT/A).Scale bar: 25 μm. 
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Figure 13.A shows, via P0 marker (red), the myelin morphology before 
and after CCI. As expected, in CCI-saline injected mice P0 was found 
aggregated and accumulated in characteristic ovoids (see white arrow in 
figure 13.A). A different result was observed in CCI-BoNT/A and CCI-
BoNT/B treated mice where the presence of myelin aggregates was lower 
and the myelin seemed similarly distributed as for naive animals. Images 
analyzed by means of RGB technique (figure 14) revealed a higher 
expression of P0 in CCI-saline treated group. One-way ANOVA 
indicated a strong significant main effect for treatment (F3,32 =3.577; 
p=0.0245) and Posthoc comparisons showed a significant effect of CCI-
BoNT/A and CCI-BoNT/B vs CCI-saline injected mice (Fisher’s PLSD 
analysis p˂0.05).  
It is important to emphasize that the RGB method for measuring the 
fluorescence is a semi-quantitative technique. As previously described in 
other studies (e.g., Marinelli et al., 2014), myelin aggregates in injured 
nerve, in comparison with uninjured nerves, lead to increased emission of 
fluorescence that is not derived from an increase of the myelin protein 
but dependent on a greater brightness issued by the ovoids containing 
fragmented myelin. In animals treated with the toxins, the absence of 
ovoids could indicate anticipation on myelin phagocytosis process in 
comparison with CCI-saline injected mice. 
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Figure 14. RGB technique reveals a higher expression of P0 in CCI-saline injected 
mice compared to CCI-BoNT/A and CCI-BoNT/B treated mice. (°p˂0.05;°°p˂0.001 vs 
saline). 
 
Figure 15.A shows IF double-stainings for GFAP (green) and PMP22 
(red). PMP22 represents 2–5% of the total amount of the peripheral 
myelin proteins expressed in SCs (Quarles, 2002). As for P0 protein, 
images were analyzed by means of RGB technique (figure 15.B). 
RGB analysis revealed a higher expression of PMP22 in CCI-saline 
injected group compared to naive. One-way ANOVA indicated a strong 
significant main effect for treatment (F3,32 =12.458; p˂0.0001) and 
Posthoc comparisons showed a significant main effect between CCI-
saline and naive, between CCI-saline and both CCI-BoNT/A and CCI-
BoNT/B and between naive and CCI-BoNT/B injected mice. Animals 
treated with BoNT/A instead did not show difference in comparison with 
naive animals (Fisher’s PLSD analysis p˂0.05). 
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Figure 15.A. Representative examples of IF images showing the expression of GFAP 
(green) and PMP22 (red) in sciatic nerve sections taken from naive, CCI-saline, CCI-
BoNT/A and CCI-BoNT/B treated mice. 15.B. RGB technique reveals a higher 
expression of PMP22 in CCI-saline injected mice. (*p˂0.05,***P˂0.0001 vs naive; 
°°p<0.001,°°°p<0.0001 vs saline). Scale bar:25 μm. 
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Also in this case, the reduction of the PMP22 protein in CCI-animals 
treated with the toxins could indicate anticipation on myelin 
phagocytosis process in comparison with CCI-saline treated mice. To be 
able to observe the dedifferentiated myelinating SCs, the second type of 
proliferating SCs, we incubated the sections with mouse anti-S100β 
antibodies (figure 16.A). One-way ANOVA for S100β expression 
indicated a strong significant main effect for treatment (F3,32 =3.497; 
p=0.0266). Posthoc comparisons showed a significant main effect 
between CCI-saline and both naive and CCI-BoNT/A, CCI-BoNT/A and 
CCI-BoNT/B and between CCI-BoNT/B injected mice and naive animals 
(Fisher’s PLSD analysis p˂0.05). These results indicated that, in injured 
nerve, the BoNT/A reduces the level of S100β to those observed in naive 
mice while BoNT/B does not alter the expression of the protein in CCI-
animals in fact, the level of S100β in CCI-BoNT/B treated mice is 
similar to CCI-saline injected animals (figure 16.B). 
Figure 16.A shows the expression of the protein Cdc2 (red), a marker of 
proliferating cells. In intact nerve the fluorescence emitted from Cdc2 is 
practically absent. Conversely, in CCI-mice the regenerative process 
associated to nerve lesion is accompanied by an increased level of Cdc2 
expression (figure 16.B). One-way ANOVA for Cdc2 indicated a strong 
significant main effect for treatment (F3,32 =36.339; p˂0.0001) and 
Posthoc comparisons showed a significant effect between CCI-saline and 
both naive and CCI-BoNT/A, CCI-BoNT/A and both naive and CCI-
BoNT/B and between CCI-BoNT/B injected mice and naive animals 
(Fisher’s PLSD analysis p˂0,05). 
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Figure 16.A. Representative example of immunofluorescent (IF) analysis of the 
dedifferentiated myelinating SCs (S100β, green) and cyclin-dependent kinase 2 (Cdc2, 
red) in naive and D7/CCI-mice treated with different drugs. 16.B. RGB evaluation of 
S100β (green) and Cdc2 (red) expression in naive and D7/CCI-mice. 
(*p˂0.05,**p<0.001,***p˂0.0001 vs naive; °p<0.05,°°°P˂0.0001 vs saline; 
#p<0.05,###p<0.0001 vs BoNT/A). Scale bar: 25 μm. 
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It is interesting to note that, while in CCI-BoNT/A injected mice the 
Cdc2 level increases about 10 times, both in CCI-saline and CCI-
BoNT/B treated animals the level of Cdc2 is only 4 times greater than in 
the naive mice. 
Furthermore, comparing the levels of GFAP and S100β of all 
experimental groups we noticed that the expression of S100β is higher in 
D7/CCI-saline and D7/CCI-BoNT/B treated mice and lower in naive and 
D7/CCI-BoNT/A while, the expression of GFAP is higher in D7/CCI-
BoNT/A treated animals and lower in the other experimental groups 
(figure 17). 
 
 
 
Figure 17. D7/CCI-BoNT/A treated animals show lower expression of S100β and 
higher expression of GFAP compared to the other experimental groups. 
(*p˂0.05,**p<0.001,***p˂0.0001 vs naive; °p<0.05,°°P˂0.001 vs saline; 
#p<0.05,###p<0.0001 vs BoNT/A). 
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Moreover, the expression of S100β in D7/CCI-BoNT/B animals is 
similar to that observed in D7/CCI-saline, while in D7/CCI-BoNT/A is 
similar to that of naive. 
After peripheral nerve damage, mast cells are the first immune cells to be 
activated. Activated mast cells degranulate and release different 
proinflammatory mediators including histamine, leukotrienes and 
chemokines which help on recruitment of hematogenous macrophages at 
the site of injured nerve (Thacker et al., 2007). In order to observe the 
expression of mast cells in injured nerve we incubated sciatic nerve 
sections with mouse monoclonal antibodies anti-CC1 (Mast Cells 
Chymase 1). Figure 18.A shows a strong increase of mast cells in 
D7/CCI mice compared to naive animals. This increase is particularly 
evident in CCI-BoNT/A injected mice (figure 18.B). One-way ANOVA 
for CC1 indicated a strong significant main effect for treatment (F3,32 
=63.463; p˂0.0001) and Posthoc comparisons showed a significant effect 
between CCI-saline and naive, CCI-BoNT/A and CCI/BoNT/B, CCI-
BoNT/A and both naive and CCI-BoNT/B and between CCI-BoNT/B 
treated mice and naive animals (Fisher’s PLSD analysis p˂0.05). 
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Figure 18.A. Representative examples of IF images showing the expression of CC1 
(green) in sciatic nerve sections in naive and D7/CCI-mice treated with different drugs. 
18.B. Strong increase expression of CC1 is observed in D7/CCI-mice compared to 
naive animals. This increase is particularly evident in CCI-BoNT/A treated mice. 
(**p˂0.001;***p˂0.0001 vs naive; °°p<0.001,°°°p<0.0001 vs saline; ###p<0.0001 vs 
B0NT/A). Scale bar: 25 μm. 
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From 2 to 3 days after injury there is an important infiltration of 
haematogenous macrophages into degenerating nerve. Macrophages 
recruitment leads to a rapid elimination of myelin debris and making it 
easier nerve regeneration. Macrophages not only remove axon and 
myelin debris, but also participate in the production of mitogenic factors 
for SCs (Dubový, 2011; Perry & Brown, 1992). To observe the 
macrophages we incubated the sections with rat anti-CD11b antibodies 
(figure 19.A). One-way ANOVA for CD11b expression indicated a 
strong significant main effect for treatment (F3,32 =14.542; p˂0.0001). 
However, despite RGB analysis revealed an increase of expression of 
CD11b in CCI-saline treated group compared to naive animals, Posthoc 
comparisons showed a significant main effect only between CCI-
BoNT/A and naive, CCI-saline and CCI-BoNT/B injected animals 
(Fisher’s PLSD analysis p˂0.05) (figure 19.B). Since macrophages 
release mitogenic factors for SCs (Dubový, 2011; Perry & Brown, 1992), 
the increase of the CD11b expression in D7/CCI-BoNT/A injected mice 
could be related to the increase of Cdc2+ and GFAP+ cells and to the 
anticipation of phagocytosis that we observed in this experimental group. 
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Figure 19.A. Representative examples of IF images showing the expression of CD11b 
(green) in sciatic nerve sections in naive and D7/CCI-mice treated with different drugs. 
19.B. Strong increase expression of CD11b is observed in D7/CCI-BoNT/A injected 
mice. (***p˂0.0001 vs naive; °°°p<0.0001 vs saline; ###p<0.0001 vs BoNT/A). Scale 
bar: 25 μm. 
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Table 3 summarizes the IF results on sciatic nerve of D7/CCI-BoNTs 
treated animals compared to D7/CCI-saline injected mice. 
 
 
Sciatic Nerve 
 
CCI-BoNT/A 15pg 
 
CCI-BoNT/B 7.5pg 
Dedifferentiated 
nonmyelinating SCs 
(GFAP) 
 
= 
 
Proliferating SCs 
(Cdc2) 
 
= 
 
Mast Cells Chymase  
(CC1) 
  
 
Macrophages 
(CD11b) 
 
= 
Dedifferentiated 
myelinating SCs 
(S100β) 
 = 
Perypheral myelin 
protein 
(P0) 
 
 
 
 
Perypheral myelin 
protein 
(PMP22) 
 
 
 
 
Table 3. Summary of IF results of the botulinum neurotoxins types A and B effects on 
sciatic nerves of D7/CCI-BoNTs treated animals compared to D7/CCI-saline injected 
mice. 
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Immunohistochemistry analysis has shown an increase of proliferanting 
SCs-GFAP+, mast cells and macrophages and a decrease of 
proliferanting SCs-S100β+ and myelin proteins in CCI-BoNT/A treated 
mice compared to CCI-saline injected group. On the contrary, CCI-
BoNT/B treated group showed only some effects produced by BoNT/A 
(a decrease of myelin proteins and an increases of mast cells) without 
modifying the other analyzed markers. 
Effect of BoNT/B on spinal cord after CCI 
After nerve injury, in the dorsal horn of the spinal cord, where primary 
afferents of damaged fibers project, dense cluster of microglial activated 
cells are detected. Massive microglial activation is also observed in the 
ventral horn, around the cell bodies of motor neurons (Scholz & Woolf, 
2007; Colburn et al., 1997). The peak of microglial activation in both 
dorsal and ventral horns occurs one week after injury and is followed by 
a slow decline over several weeks. This cell activation, characterized by 
phosphorylation of p38 MAP kinase (p-p38), induces the production and 
secretion of proinflammatory cytokines that contribute to the onset and 
maintenance of pain hypersensitivity (Beggs & Salter, 2007). The block 
of microglial response with minocycline can prevent nerve injury-
induced hypersensitivity in rat (Calvo & Bennett, 2012). To be able to 
observe microglial cells, members of the monocyte/macrophage family, 
we incubated transverse sections of L4/L5 spinal cord segment of 
D7/CCI-saline and D7/CCI-BoNT/B 7.5 pg/paw treated mice with rat 
monoclonal antibodies anti-CD11b and with rabbit polyclonal antibodies 
anti-p-p38 to observe the activation of the same cells. Figure 20.A shows 
immunoreactivity (IR) images of ipsilateral-side of dorsal horn of 
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D7/CCI-saline and D7/CCI-BoNT/B injected mice. For analysis of 
labeling of CD11b positive IR-cells, and their colocalization with p-p38, 
the number of positive IR cells was quantified (figure 20.B). One-way 
ANOVA for CD11b and CD11b/p-p38 positive cells expression for 
treatment indicated that the animals injected with the toxin showed no 
difference compared to control animals (CD11b+: F1,10 =0.804; 
p=0.3911; CD11b+/p-p38+: F1,10 =3.586; p=0.0875). Similar results have 
been obtained from the analysis of ipsilateral-side of ventral horn (figure 
21.A and figure 21.B). One-way ANOVA for treatment for CD11b and 
CD11b/p-p38 positive cells expression in ventral horn indicates no 
difference between experimental groups (CD11b+: F1,10 =0.028; 
p=0.8716; CD11b+/p-p38+: F1,10 =0.000). 
 
 
 
 
91 
 
 
Figure 20.A. Representative examples of IR images showing the expression of CD11b+ 
(green) and CD11b+/p-p38+ (yellow) cells in dorsal horn of spinal cord sections in 
D7/CCI-saline and D7/CCI-BoNT/B 7.5 pg injected mice. 20.B. Analysis of CD11b 
and CD11b/p-p38 positive cells expression in dorsal horn indicates no difference 
between experimental groups. Scale bar: 25 μm. 
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Figure 21.A. Representative examples of IR images showing the expression of CD11b+ 
(green) and CD11b+/p-p38+ (yellow) cells in ventral horn of spinal cord sections in 
D7/CCI-saline and D7/CCI-BoNT/B 7.5 pg injected mice. 21.B. Analysis of CD11b 
and CD11b/p-p38 positive cells expression in ventral horn indicates no difference 
between experimental groups. Scale bar: 25 μm. 
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In case of damage to the PNS, the density of spinal cord microglia 
increases through the migration of these cells from other sites and 
through local proliferation. In response to traumatic nerve injury 
microglia exhibit variable alterations in functions and morphologies 
(from a resting state, where the cell body is small and there are long and 
thin processes, into an effector state in which the cells present an 
amoeboid form) (Calvo & Bennett, 2012). These changes are associated 
with different activation states of microglia (Ji et al., 2013). From images 
obtained with IR technique we also observed that, differently from CCI-
saline injected mice, in CCI-BoNT/B treated animals the microglial 
morphology did not show the typical amoeboid form of the strong 
activated state. Microglial recruitment and activation in dorsal and 
ventral horn is accompanied by proliferation and activation of astrocytes 
in the ipsilateral-side of spinal cord. Compared with the microglial 
response, astrocyte proliferation begins relatively late, progresses slowly 
and is sustained for a longer period (Scholz & Woolf, 2007). Together 
with microglia, astrocytes play a critical role in chronic pain sensitization 
and their activation is correlated with chronic pain behaviors (Wang et 
al., 2009; Liu et al., 2012). In spinal cord astrocytes, damage to 
peripheral nerves induces hypertrophy, hyperplasia, proliferation, 
increased of glial fibrillary acidic protein (GFAP) and, in severe cases, 
scar formation (Tsuda et al., 2011). Previous studies have shown that 
suppression of astrocyte proliferation, and activation, produces a 
recovery from tactile allodynia (Tsuda et al., 2011). 
Figures 22 and 23 show IR images for astrocytes (GFAP, green) and 
their colocalization with p-p38 (yellow) on ipsilateral-side of dorsal and 
ventral horn (figure 22.A and 23.A. respectively) of D7/CCI-saline and 
D7/CCI-BoNT/B treated mice. 
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Figure 22.A. Representative examples of IR images showing the expression of GFAP+ 
(green) and GFAP+/p-p38+ (yellow) cells in dorsal horn of spinal cord sections in 
D7/CCI-saline and D7/CCI-BoNT/B 7.5 pg injected mice. 22.B. Analysis of GFAP and 
GFAP+/p-p38 positive cells expression indicates a strong significant main effect for 
treatment (***p˂0.0001, for GFAP+;##p˂0.001, for GFAP+/p-p38+). Scale bar: 25μm. 
95 
 
 
Figure 23.A. Representative examples of IR images showing the expression of GFAP+ 
(green) and GFAP+/p-p38+ (yellow) cells in ventral horn of spinal cord sections in 
D7/CCI-saline and D7/CCI-BoNT/B 7.5 pg treated mice. 23.B. Analysis of GFAP and 
GFAP/p-p38 positive cells expression indicates a strong significant main effect for 
treatment only for GFAP (*p˂0.05). Scale bar: 25 μm. 
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One-way ANOVA for GFAP and GFAP/p-p38 positive cells expression 
on ipsilateral-dorsal horn (figure 22.B) indicated a strong significant 
main effect for treatment for both markers (GFAP+: F1,10 =59.387, 
p˂0.001; GFAP+/p-p38+: F1,10 =22.510, p=0.0008; Fisher’s PLSD 
analysis p˂0.05). Unlike dorsal horn, in ipsilateral-side of ventral horn 
(figure 23.B) One-way ANOVA showed only a strong significant GFAP 
positive cells expression (GFAP+: F1,10 =5.604, p=0.0395; Fisher’s 
PLSD analysis p˂0.05; GFAP+/p-p38+: F1,10 =2.169, p=0.1715). 
As already mentioned, microglia and astrocyte proliferation and 
activation are correlated with chronic pain behaviors. The resting state of 
the microglia and the reduced number of activated astrocytes, observed 
in dorsal horn of ipsilateral-side of spinal cord, may explain the analgesic 
effect of BoNT/B in mice noted during the behavioral tests. In ventral 
horn of both experimental groups we have not observed differences in 
the number of activated cells, however, in CCI-BoNT/B injected mice, 
IR images have highlighted a mild/moderate reactive astrogliosis. 
Reactive astrogliosis is a spectrum of changes in astrocytes that occur in 
response to all forms of injury and disease in CNS. In its mild and 
moderate forms, reactive astrogliosis can be resolved and cells can 
reacquire a morphology similar to that in healthy tissue (Sofroniew, 
2010). The presence of mild/moderate reactive astrogliosis in the ventral 
horn of CCI-BoNT/B treated animals could be related to the reduced 
performance observed during behavioral testing in this experimental 
group.  
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Discussion 
The results reported in this thesis indicate that a single intraplantar 
administration of BoNT/B (5 or 7.5 pg/paw) induces antiallodynic effect 
in mice subjected to Chronic Constriction Injury (CCI) of sciatic nerve. 
This effect was long-lasting and almost immediate, starting from the day 
after the injection, and lasted for at least 30 days. 
However, despite the clear evidence of a strong analgesic effect of the 
neurotoxin, behavioral tests on functional recovery showed that BoNT/B 
interferes, if not even compromises, the injured limb functional 
rehabilitation. Results of immunofluorescence (IF) experiments 
associated to functional data revealed that BoNT/B, acting directly or 
indirectly on neuronal and non-neuronal cells of both peripheral and 
central nervous system: i) decreases the expression of peripheral myelin 
proteins (P0 and PMP22) suggesting an increase of the degradation and 
elimination processes, ii) changes the expression of mast cells (CC1) in 
sciatic nerve and in dorsal and ventral horns of spinal cord, iii) alters the 
activation of macroglia and microglia cells (GFAP and CD11b) leading 
to the development of reactive astrogliosis, id est an inflammatory 
process of the CNS. Previous experiments have already shown the action 
of BoNT/A and BoNT/B as analgesics in several pain models (Cui et al., 
2004; Luvisetto et al., 2006; Huang et al., 2011; Marinelli et al., 2010, 
2012; Park et al., 2015; Ramachandran et al., 2015; Huang et al., 2011). 
In particular, in animals subjected to peripheral nerve injury (CCI of 
sciatic nerve or L5 nerve ligation) it was demonstrated that a single non-
toxic dose of BoNT/A or BoNT/B into plantar surface of injured paws 
was sufficient to induce antiallodynic effects and counteract pain 
symptoms (Marinelli et al., 2010; Park et al., 2015; Luvisetto et al., 
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2007). The results obtained in our experiment confirm the antiallodynic 
effect of BoNT/B on mechanical nociceptive threshold. It has been 
reported that BoNT/A, in addition to having analgesic effects, also 
accelerates functional recovery in CCI-mice restoring the normal weight 
bearing value on the two hindlimbs in incapacitance test and improving 
SSI scores of the foot print test (Marinelli et al., 2010). Differently from 
this positive effect of BoNT/A on functional recovery, the results of our 
study showed that BoNT/B, independently of the dose administered, 
slows down functional rehabilitation of mice. This effect is observed for 
most of the period of monitoring of animals and, except in the last days 
of observation, the animals treated with the neurotoxin showed no 
differences in performance compared to CCI-saline injected animals. 
CCI-BoNT/B treated mice still showed clear signs of atrophy of the 
injured paw even at 101 days post- surgery. With the aim to better define 
the effect of BoNT/B on neuropathic pain of CCI-mice, IF experiments 
were associated to behavioral tests. After axonal injury, the distal portion 
of the nerve undergoes progressive degeneration due to a series of events 
that induce the degradation of cytoskeletal proteins. In order to evidence 
structural changes in damaged nerve, we have analyzed with IF 
technique the expression of NF200, marker of neurons intermediate 
filaments. By observation of the IF images we found a tissue disjointed 
and broken up in all CCI-animals to indicate that both BoNT/A and 
BoNT/B do not affect cytoskeletal proteins. Further changes in the 
structure of the nerve can be detected by analyzing the distribution and 
expression of the peripheral myelin protein P0 and PMP22. It is 
important to consider that, as the axon disappears, Schwann Cells (SC), 
having lost axonal contact, become able to isolate small whorls of myelin 
and generate ovoids containing fragmented myelin (Röyttä et al., 1987; 
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Dubový, 2011). SCs play a key role in the breakdown of the myelin 
sheath and in the clearance of its debris. SCs clear myelin debris in three 
distinct ways: they degrade their own myelin, phagocyte extracellular 
myelin debris, and present myelin to macrophages (Vargas & Barres, 
2007). Rapid clearance of myelin appears to be the most important 
precondition for axonal regeneration after peripheral nerve injury due to 
the presence of axon growth inhibitors in peripheral nerve myelin 
(Barrette et al., 2008). Based on this evidence, by means of IF analysis 
we observed that in CCI-saline injected mice P0 and PMP22 peripheral 
myelin proteins are aggregated and accumulated in characteristic ovoids 
while in CCI-BoNT/A and CCI-BoNT/B treated mice myelin seems 
similarly distributed as for naive animals and the ovoids containing 
fragmented myelin are reduced. We suggest that, in animals injected with 
the neurotoxins in comparison with saline-treated mice, the absence of 
ovoids, the naive-like distribution of myelin and the low expression of P0 
and PMP22 could indicate anticipation of myelin phagocytosis process. 
As previously reported, SC have an important role in regenerative 
processes (Vargas & Barres, 2007; Barrette et al., 2008). In injured 
nerves, SCs regain capacity to proliferate and their migration facilitates 
peripheral nerve regeneration (Han et al., 2007). After injury, 
myelinating and nonmyelinating SCs change their phenotype from 
differentiated to immature cells, acquire the expression of molecules 
characteristic of embryonic development and up-regulate cytoskeletal 
constituents such as GFAP (marker of dedifferentiated nonmyelinating 
SCs) and S100β (marker of dedifferentiated myelinating SCs) (Berg et 
al., 2013; Bhatheja & Field, 2006; Hayashi et al., 2007). In accord with 
these data, our IF analysis show increased expression of GFAP, S100β 
and Cdc2 (marker of proliferating cells) in CCI-saline injected mice 
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compared to naive animals. Animals treated with BoNT/B did not show 
differences in the expression of these markers in comparison with CCI-
saline injected group, indicating that BoNT/B does not modify the 
activity of SCs after nerve injury. On the contrary, we found a great 
increase of GFAP and Cdc2 and a clear reduction of S100β expression in 
CCI-BoNT/A injected mice in comparison with CCI-saline group. As 
described in previous studies, BoNT/A is able to accelerate the process of 
nerve regeneration stimulating the SCs proliferation (Marinelli et al., 
2010, 2012). The increased expression of GFAP and Cdc2 in BoNT/A 
treated group observed in our experiment confirms this BoNT/A ability. 
Previous studies also demonstrated that SC-mediated S100β secretion is 
required for peripheral nerve regeneration (Perrone et al., 2008). In the 
nervous system S100β is expressed in Schwann Cells, astrocytes and in 
certain neuronal population. It has been demonstrated that S100β, 
released by the same cells that produce it, can act in autocrine, paracrine 
or endocrine manner with concentration-dependent effects (Michetti et 
al., 2012). In particular, it has been reported that the maintenance of 
physiological concentrations of S100β contributes to promote neurite 
extension, it protects neuron survival and helps to regulate the muscle 
development and regeneration (Businaro et al., 2006; Michetti et al., 
2012; Sorci et al., 2003). On the contrary, higher concentrations of S100β 
increase the production of reactive oxygen species in neurons and, up-
regulating inducible NOS, induce NO-dependent death of neurons. 
Furthermore, several researches have shown a correlation between high 
S100β level in biological fluids (blood, urine, saliva, CSF) and different 
pathological conditions, such as neuroinflammatory/neurodegenerative 
disorders, brain trauma/injury and cardiac events (Michetti et al., 2012; 
Donato et al., 2013). By means of IF analysis we observed: i) a strong 
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reduction of S100β expression in CCI-BoNT/A injected mice in 
comparison with CCI-saline treated group and, ii) similar expression of 
S100β in CCI-BoNT/A treated group to that observed in naive animals. 
We hypothesize that the expression of S100β observed in CCI-BoNT/A 
injected animals could be associated to an extracellular release of the 
protein by SCs similar to that in physiological conditions, and explain the 
positive effect of BoNT/A observed on nerve regeneration. Conversely, a 
higher expression of S100β, such as that in CCI-saline and CCI-BoNT/B 
treated animals, could explain the functional impairment observed in 
these two experimental groups and could be ascribed to an up-regulation 
of inducible NOS and to the consequent death of neurons. To confirm 
this hypothesis further experiments should be carried out, investigating 
the extracellular concentrations of S100β in naive and CCI-mice treated 
with the neurotoxins, and evaluating a possible correlation between 
S100β release and S100β expression in SCs. 
The activation of immune cells that occurs after the nerve damage was 
examined by IF technique. The analysis showed an increase of mast cells 
in CCI-mice compared to naive animals. This enhancement has been 
particularly evident in CCI-BoNT/A injected mice. Furthermore, in CCI-
BoNT/A treated group, but not in the other CCI-group, was also 
observed a great increase of macrophages. Activated mast cells release 
different pro-inflammatory mediators and chemokines which help the 
recruitment of hematogenous macrophages at the site of injured nerve 
(Thacker et al., 2007). Instead, macrophages remove axon and myelin 
debris and participate in the production of mitogenic factors for Schwann 
Cells (Dubový, 2011; Perry & Brown, 1992). The increase of mast cells 
and macrophages observed in CCI-BoNT/A injected group, compared to 
other CCI-groups, once again confirms a role of this neurotoxin on 
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facilitation of nerve regeneration. On the contrary, the increase of mast 
cells, not accompanied by an enhancement of macrophages and 
proliferative SCs, that we observed in CCI-BoNT/B treated animals, 
could indicate a pro-inflammatory effect of this serotypes rather than a 
pro-regenerative effect. 
Overall, these results indicate that, at peripheral level, BoNT/A and 
BoNT/B act in different manner. Particularly, as concerns the structural 
alterations associated to nerve injury, BoNT/B seems to produce only 
some effects induced by BoNT/A, as the anticipation of myelin 
phagocytosis processes, but, unlike BoNT/A, does not modify the 
expression of markers related to the nerve regeneration such as GFAP, 
S100β, Cdc2 and CD11b. Rather, BoNT/B appears to promote the 
expression of mast cells which, releasing a greater amount of pro-
inflammatory molecules could have also an effect on functional recovery 
of animals.  
Previous studies suggested that BoNTs can act not only peripherally but 
also at the central level (Cui et al., 2004; Luvisetto et al., 2006; Marino et 
al., 2014; Park et al,. 2015; Mika et al., 2011; Marinelli et al., 2012). In 
order to observe the effects of BoNT/B on spinal cord we carried out IF 
analysis on ipsilateral-side of dorsal and ventral horns. Activation of 
microglial (Cd11+/p-p38+) and astrocytes (GFAP+/p-p38+) in both 
dorsal and ventral horns was investigated in CCI-saline and CCI-
BoNT/B 7.5 pg/paw treated mice. Microglia and astrocytes play a critical 
role in chronic pain sensitization and their proliferation and activation are 
correlated with chronic pain behaviors (Wang et al., 2009; Liu et al., 
2012). By IF analysis we revealed that CCI-BoNT/B injected group 
showed no difference compared to CCI-saline treated animals for CD11b 
and CD11b/ p-p38 positive cells expression in both dorsal and ventral 
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horn. However, we also observed that, differently from CCI-saline 
injected mice, in CCI-BoNT/B treated group the microglial morphology 
did not show the typical amoeboid form of the strong activated state as in 
CCI-saline injected group, rather, the form was similar to that observed 
in the resting state, where the cell body is small with long and thin 
processes. Different results were obtained from the analysis of astrocytes. 
In particular, IF analysis showed a strong effect of the BoNT/B in dorsal 
horn, where the astrocytes appear to be less numerous and less activated 
compared to the CCI-saline treated group. Unlike dorsal horn, in 
ipsilateral-side of ventral horn the number of astrocytes decreased in 
CCI-BoNT/B injected animals and, although the number of activated 
cells was similar between the two experimental groups, IF images 
highlight a mild/moderate reactive astrogliosis induced by BoNT/B, as 
indicated by the intense expression of p-p38 in GFAP+ cells and by its 
hypertrophic morphology. Previous studies have already showed that, 
after CCI of sciatic nerve, microglia activation in spinal cord can be 
reduced by peripheral administration of BoNT/A in rats (Mika et al., 
2011). Vacca et al. (2013) have also shown that treatment with BoNT/A, 
3 days post-CCI, induces strongly reduction of activated and not 
activated astrocytes and microglial cells in dorsal and ventral horns of 
mice. Marinelli and colleagues (2012) showed that BoNT/A, 
administrated into plantar surface of injured paws of CCI-mice, can be 
carried by the peripheral nerve endings to the spinal cord where it can be 
transcytosed by nociceptive fibers to astroglial cells. Our results showed 
that, as BoNT/A, also BoNT/B acts at central level but with different 
mechanisms. In spinal cord we found that BoNT/B reduces the activation 
state but not the expression of microglial cells while the astrocytes 
appears reduced and, in the dorsal horn also less activated. The resting 
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state of microglia and the reduced number of activated astrocytes 
observed in dorsal horn of spinal cord, may explain the analgesic effect 
of BoNT/B observed during the behavioral tests in mice. In particular, 
BoNT/B, acting on astrocytes, probably by transcytosis, could inhibit the 
glutamate release from astroglial cells and, consequently, contributes to 
the reduction of pain. Effectively, the possibility that BoNTs can be 
transcytosed to astrocytes has been already suggested (Marinelli et al., 
2012), as it has been also demonstrated the ability of BoNT/B to inhibit 
the release of glutamate by astrocytes cultures (Jeftinija & Stefanovic, 
1997). Conversely, the presence of reactive astrogliosis in the ipsilateral-
side of ventral horn in CCI-BoNT/B treated animals could explain the 
reduced performance observed during behavioral testing and the failure 
of functional recovery, testified by marked atrophy of the injured paw of 
CCI-BoNT/B mice at 101 days post-surgery.  
The results of our study confirm BoNT/B as a powerful biological 
molecule that can reduce neuropathic pain symptoms for a long period of 
time. However, we provide the first evidence that BoNT/B, although it 
alleviates neuropathic pain-related behavior, increases the expression of 
cells that release pro-inflammatory molecules in injured nerve and, in 
ventral horns of spinal cord, induces reactive astrogliosis development 
that could lead to glial scar formation and irreversibly compromise the 
functional recovery. 
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Conclusion 
Based on our results, we believe that the use of BoNT/B as therapeutic 
alternative to BoNT/A for the treatment of pain syndromes must be 
avoided. The development of astrogliosis observed in ventral horn of 
spinal cord and the clear signs of atrophy of the injured paw of mice at 
101 days post-CCI are compatible with the possibility that BoNT/B can 
induce formation of a glial scar, compromising the functional 
rehabilitation.  
Therefore, on the basis of this evidence, we do not recommend the use of 
BoNT/B in pain conditions associated with nerve injury as long as the 
molecular pharmacology and the mechanism of action of neurotoxin will 
not fully understood and more information becomes available. 
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